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Background and Hypotheses 
 
The ability of skeletal muscle and tendon to adapt to environmental 
changes, injury, illness and other physiological conditions is critical in 
determining the overall health, mobility and athletic performance of an individual.  
Determining the cellular and molecular mechanisms behind the adaptation of 
skeletal muscle and tendon provides important insights into basic biological 
processes and the design of therapies for the treatment of diseases and injuries.  
Several cytokines have been identified as important regulators of skeletal muscle 
mass.  One of the most potent cytokines that regulate skeletal muscle mass is 
myostatin (GDF-8).  Myostatin is a member of the TGF-ß superfamily of 
cytokines and the targeted inhibition of myostatin results in an up to two-fold 
increase in skeletal muscle mass (54, 84).  Due to the profound increase in 
skeletal muscle mass that occurs as a result of the deficiency of myostatin, much 
interest has focused on the targeted inhibition of myostatin in the treatment of 
muscle injuries and wasting diseases (81). 
While the inhibition of myostatin results in a clear muscle mass phenotype, 
arguably with as great an impact on muscle mass as any other single cytokine, 
the full range of mechanical consequences of myostatin deficiency are not 
known.  Using classical muscle mechanics experimental techniques in the 
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myostatin-deficient mouse model, along with contemporary molecular biology 
experimental techniques, this doctoral dissertation determined the mechanisms 
by which the deficiency of myostatin regulates the structure and function of 
skeletal muscles and of tendons.  This introductory chapter describes the 
molecular biology of myostatin, the structure, function and adaptation of skeletal 
muscle and tendon tissue, and preliminary experiments that were critical for the 
research studies in Chapters II and III.   
In Chapter II, the impact of the deficiency of myostatin on the contractile 
properties and extracellular matrix composition of skeletal muscle was 
determined.  We hypothesized that the deficiency of myostatin increases the 
maximum tetanic force (Po), but decreases the specific Po (sPo) of muscles and 
increases the susceptibility of muscles to contraction-induced injury.  To test 
these hypotheses, we measured the in vitro contractile properties of EDL and 
soleus muscles from MSTN+/+, MSTN+/- and MSTN-/- mice and subsequently 
subjected the muscles to a lengthening contraction protocol.  We also 
determined the impact of myostatin on the connective tissue composition of 
skeletal muscle.  We hypothesized that the deficiency of myostatin decreases the 
type I collagen content of muscle connective tissue.  The type I collagen content 
of EDL and soleus muscles from MSTN+/+, MSTN+/- and MSTN-/- mice was 
determined, as well as the expression of type I collagen in cultured skeletal 
muscle myotubes treated with myostatin.  The results from Chapter II indicate 
that the deficiency of myostatin increases the Po of muscles, increases the 
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susceptibility of muscles to injury and decreases the type I collagen content of 
skeletal muscle connective tissue.   
The experiments on skeletal muscles in Chapter II lead to the exploration 
of the role of myostatin in the regulation of tendon structure and function in 
Chapter III.  We hypothesized that the deficiency of myostatin results in smaller, 
stiffer, and more brittle tendons.  To test this hypothesis, we measured the 
stress-strain relationships of tendons from the tibialis anterior muscles of 
MSTN+/+ and MSTN-/- mice.  We also measured the expression of structural and 
cell cycle regulatory genes in whole tendon tissue and in cultured tendon 
fibroblasts treated with myostatin.  Our studies of tendons lead to the novel 
finding that, in addition to regulating skeletal muscle structure and function, 
myostatin also regulates the structure and function of tendon tissue.  
Skeletal Muscle Structure and Function 
Skeletal muscles consist of hundreds to thousands, and sometimes 
millions, of long, multinucleated fibers organized together by an extracellular 
matrix.  There are three general layers of extracellular matrix, or connective 
tissue, in muscles – the outermost layer is the epimysium, the intermediate layer 
is the perimysium and the inner most layer is the endomysium.  Understanding 
the structure and function of each of these three layers requires a hierarchical 
approach.  The structure and function of the epimysium and perimysium will be 
discussed in a whole body and tissue level biomechanical context, whereas the 
structure and function of the endomysium will be discussed in the context of 
cellular and molecular biomechanics. 
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Epimysium and perimysium.  The epimysium covers the surface of the 
muscle and has important roles in force transmission and insulation of the 
muscle (46).  Processes from the epimysium extend into muscle tissue and form 
the second layer of connective tissue, the perimysium.  The perimysium contains 
blood vessels, nerves and lymphatic ducts, and structurally divides muscle fibers 
into functional groups called fascicles.  The orientation of fascicles are important 
determinants of the direction of the force a muscle can generate (55).  The 
variation in the number of fascicles allows muscles to adopt a complex geometry 
and facilitate complicated movements at joints.  There is a trade-off between the 
angle at which the fascicles are oriented and the amount of force the fascicles 
are able to generate.  The angle at which the fascicles are oriented to the 
insertion is known as the angle of pennation (θ). The force that a muscle fiber 
can generate is proportional to the cosine of θ (50).  As θ goes from 0º to 90º, the 
cosine of θ goes from 1 to 0.  Therefore, a fascicle can generate the greatest 
amount of force when θ is 0º, and can generate no force when θ is 90º.  An 
interesting feature about the angle of pennation is that, as muscle fibers undergo 
hypertrophy, there is an increase in θ (50).  While a muscle that experiences 
hypertrophy is generally able to generate a greater total force, due to the cosine 
relationship between θ and net force development, the muscle must undergo 
relatively greater increases in hypertrophy to generate greater net forces across 
a joint. 
In addition to providing a hierarchical structure to skeletal muscle fibers, 
the epimysium and perimysium may also protect an injured muscle from further 
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damage.  The epimysium and perimysium are composed mostly of the fibrillar 
collagens, type I and type III (43).  These collagens act as molecular springs and 
exist in parallel with the muscle fibers (9).  While some debate still exists on the 
topic, the epimysium and perimysium are thought to protect muscle fibers against 
stretch induced injury by taking up the load during stretch and protecting the 
skeletal muscle fibers from further injury (4).    
Endomysium.  The innermost layer of connective tissue is the 
endomysium.  The endomysium is composed of two layers of mostly type I and 
type III collagen that fuse to form a sheet-like structure that inserts into the 
tendon (43).  The endomysium is important in transmitting forces generated 
within the muscle to the tendon as well as laterally to other muscle fibers (63).  
The endomysium is connected to the basement membrane that directly 
surrounds each muscle fiber.  The basement membrane is composed mostly of 
type IV collagen (43).  Unlike the fibrillar type I and type III collagen, type IV 
collagen forms a mesh-like network that surrounds the muscle fiber (9).  
Embedded within the endomysium and basement membrane are two classes of 
proteins that have important functions.  The first class of proteins are responsible 
for force transmission from the sarcomeres through the intramuscular connective 
tissue and eventually to tendons and bone.  These proteins, such as integrin and 
fibronectin, provide a mechanical link between the structural proteins of muscle 
fibers with the collagen network of the extracellular matrix (37).  The second 
class of proteins are released from the matrix after injury and are important in 
initiating the recovery of muscle from injury (24, 30, 76).  This second class of 
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proteins will be discussed in the section that focuses on contraction-induced 
injury. 
Molecular Mechanisms of Force Transmission in Skeletal Muscle.  The 
structure within muscle fibers that is responsible for the generation of force is the 
sarcomere.  The sarcomere is composed of three major components – the thick 
filament that is surrounded by six thin filaments that are shared with the six 
surrounding thick filaments.  The thin filaments are imbedded in the Z-disks at 
the end of each sarcomere (73).  The thick filament contains the protein that is 
the molecular motor that drives muscle contraction, myosin heavy chain.  The 
head of the myosin molecule interacts with the actin molecules on the thin 
filaments.  The myosin binding sites on the actin molecule are regulated by the 
troponin protein complex.  The thick filaments are anchored to the Z-disks via the 
proteins titin and nebulin.  The Z-disks are responsible for transmitting the force 
generated within the sarcomere to the extracellular matrix (ECM) (11, 67).  The 
Z-disks accomplish this by linking to structures that transmit force both laterally 
and longitudinally.   
For the lateral transmission of force, the Z-disks link with a structure at the 
plasma membrane called the costamere.  The Z-disk interacts with the 
costamere via the dystrophin class of proteins (11, 67).  The dystrophin proteins 
link the membrane bound dystroglycan complex, which is in turn linked to the 
extracellular matrix via laminin and fibronectin.  Longitudinal force transmission is 
accomplished via a mechanical linkage between the Z-disk and the actin 
cytoskeleton of the muscle cell (55).  This force is transmitted to the ends of the 
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fibers at the location where the fibers insert into tendons.  This linkage comes 
about due to the association between the actin cytoskeleton with vinculin and 
talin (12).  Vinculin and talin transmit force across the plasma membrane using 
the fibronectin receptor that is bound to fibronectin in the ECM (3, 12).  The 
contraction of a muscle is therefore dependent upon the effective transmission of 
the forces generated by the interaction between actin and myosin molecules 
through structural proteins, out to the endomysium and eventually to tendons that 
link the muscles  to bone.   
Skeletal Muscle Contraction.  There are three general types of skeletal 
muscle contractions.  The contractions are defined by the change in fiber length 
that occurs subsequent to muscle activation (18).  During a shortening 
contraction, the force generated by the muscle is greater than the load placed on 
the muscle.  Consequently, the distance between the distal and proximal ends of 
a muscle decrease and positive work is performed.  During an isometric 
contraction, the force generated by the muscle is equal to the load on the 
muscle.  Consequently, the length of the muscle fiber does not change 
significantly and no net work is done.  The amount of force a muscle can 
generate is greatest during an isometric contraction and is referred to as the 
maximum isometric tetanic force (Po).  The specific maximum tetanic force (sPo) 
is the value Po normalized to the CSA.   During a lengthening contraction, the 
load on the muscle is greater than the force generated by the muscle.  
Consequently, the distance between the ends of the muscle increases and there 
is net negative work done.  Contraction-induced injury occurs during lengthening 
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contractions when the magnitude of the opposing force is sufficient to disrupt the 
ultrastructure of individual or groups of sarcomeres (18).  Clinically, contraction-
induced injuries are commonly referred to as muscle strains. 
Tendon Structure and Function 
 Tendons are connective tissue structures responsible for the transmission 
of the force developed by muscles to bones, and in doing so, enable the 
contraction of muscles to lead to joint movements and locomotion.  Force 
transmission may also occur in the opposite direction, from bone through tendon 
to muscle.  The transmission of force in this direction allows for the storage of 
elastic energy within the tendon and muscle, but may also lead to damage to the 
muscle.  During a lengthening contraction, tendons may protect muscle from 
injury by limiting the strain placed on muscle fibers (23). 
 Tendon Structure.  Tendon tissue is arranged in an hierarchical order, 
similar to skeletal muscle.  Fibroblasts are the major cellular component of 
tendons and consequently are responsible for the maintenance, repair, 
modification of the tendon ECM (37).  The fundamental anatomical structure in 
tendons is the tendon fiber (31, 82).  The tendon fiber is composed of collagen 
fibrils and other structural proteins and is wrapped in a layer of connective tissue 
that carries nerve endings, capillaries and lymphatic ducts.  Fibers coalesce to 
form fascicles, that are surrounded by a second connective tissue layer that 
contains arterioles, venules and axons of nerve cells.  Tendon fascicles are 
surrounded by a third connective tissue structure called the epitenon.  The 
synovial sheath surrounds the epitenon and secretes synovial fluid that helps to 
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cushion the tendon and reduce friction from adjacent tissues as the tendon is 
stretched and relaxed.  Early damage to tendon tissue can result in an 
overproduction of tendon synovial fluid (42).  Swelling in the synovium is referred 
to as tenosynovitis and is an early clinical diagnostic sign that tendon tissue is 
injured.  Tendons are linked to muscle tissue by myotendinous junctions located 
at the ends of the tendon (82).  Many muscles have an aponeurosis or internal 
tendon, that is an extension of the tendon into the muscle tissue.  At the other 
end, tendons are connected to bone by strong fibrous structures called entheses 
(6).   
Tendon Mechanical Properties.  The proteins and molecules that make up 
the tendon can be divided into two categories, based upon the mechanical 
properties they impart to tendon – stiffness and viscoelasticity.  The stiffness of a 
tendon is an important determinant of the ability of the tendon to store elastic 
energy.  Type I and type III collagens are the major proteins that determine the 
stiffness of a tendon (37).  Both type I and type III collagens are triple helical 
molecules (9).  The amino acid residues that face the inner core of the triple helix 
are able to form hydrogen bonds with each other, and it is this hydrogen bonding 
that provides much of the molecular basis for the stiffness material property of 
tendons (45).  As the tendon is stretched the hydrogen bonds between amino 
acid residues are broken and the breaking of these bonds gives off energy in the 
form of heat (61).  The tendon must be able to dissipate this heat energy, 
because if the energy is not properly dissipated, the structural covalent bonds of 
molecules in the tendon can be broken and this will lead to tendon rupture.   
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The second category of molecules impart the viscoelastic properties of 
tendons.  Viscoelasticity is important because this allows the tendon to resume 
its original shape after the application of a strain (37).  This second category of 
molecules is comprised of elastin, proteoglycans and glycosaminoglycans.  
These molecules are highly hydrophilic, and their ability to bind water molecules 
allows for them to transfer the heat produced by the breaking of hydrogen bonds 
within collagen to the water molecules, that are further able to dissipate heat 
energy into surrounding tissues (61). 
An additional factor that is an important determinant of the mechanical 
properties of tendons is the covalent cross-linking between collagen molecules.  
Cross-linking  reduces the friction between collagen molecules as they are 
stretched (61).  The consequence of greater cross-linking between collagen 
molecules is that the tendon becomes stiffer and can store mechanical energy 
more efficiently without losing this energy in the form of heat.  Cross-linking 
between collagen molecules can occur via an enzymatic or a non-enzymatic 
mechanism.  The lysyl oxidase enzyme generates aldehyde groups on lysine 
residues in collagen molecules (19).  These highly reactive aldehyde groups can 
form stable covalent bonds with other lysine residues.  Non-enzymatic cross-
linking can occur when the amino group on the side-chains of amino acid 
residues come into contact with a reducing sugar (65).  In addition to cross-
linking amino acid residues between collagen molecules, this reaction generates 
compounds called advanced glycation end products (AGEs) (65).  These AGEs 
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accumulate in the tissue and can disrupt the hierarchical structure of tendons and 
lead to tissue damage. 
The structural and mechanical properties of tendons change with aging 
and physical activity.  Compared with younger tendons, aged tendon is stiffer 
(60), has a lower rate of type I collagen synthesis (59) and is more prone to 
rupture (33, 60). The density of fibroblasts in tendon is highest at birth and 
steadily declines throughout the lifespan (56, 59).  While conflicting reports have 
been published (40, 79), tendon typically adapts to chronic physical activity by 
increasing CSA, stiffness, peak stress, peak strain, type I collagen synthesis and 
fibroblast activity (34, 47, 48, 72, 80, 86, 87). 
Regulation of Muscle Growth and Atrophy 
 The regulation of muscle growth and atrophy involves a sensitive balance 
between protein synthesis and degradation.  Minor damage to muscle fibers 
causes an adaptive response in which damaged proteins are removed and new 
proteins are synthesized (20).  With repetitive minor damage, such as the 
damage that occurs during exercise sessions that involve repeated lengthening 
contractions, there is a net increase in protein synthesis (17).  This increase in 
protein synthesis increases both the size and Po of individual fibers.  However, if 
the damage to muscle is of sufficient magnitude, such as the damage that occurs 
following a muscle "strain", there is a robust activation of proteolytic enzymes 
that cause the breakdown of both damaged proteins and healthy, functional 
proteins (21, 30).  The premature breakdown of functional proteins leads to 
muscle atrophy and a decrease in both the size and Po of individual fibers.  
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Understanding the mechanical, cellular and molecular mechanisms that control 
muscle growth and atrophy is critical in improving the current treatments 
available for muscle injuries and diseases, as well as enhancing athletic 
performance and maximizing strength gains in exercise programs.  
Mechanical damage to muscle fibers can initiate a series of events that 
lead to muscle hypertrophy and an increase in Po.  Sarcomeres are usually 
damaged only during lengthening contractions (10, 51, 52).  The process of 
mechanical damage to sarcomeres is best explained in terms of the length-
tension relationship of the sarcomere.  The tension a muscle fiber can develop is 
proportional to the amount of overlap between the thick and thin filaments (74).  
The point of maximum tension occurs when the muscle is at a length at which the 
maximum number of cross bridges can be formed.  This is the point at which the 
load opposing the muscle contraction is equal to the tension generated by the 
muscle, an isometric contraction.  As an actively contracting muscle is 
lengthened, the available cross bridge binding sites steadily decreases.  The 
forces transmitted to the sarcomeres from the external load can damage the 
ultrastructure of the sarcomere, and this disruption of sarcomere ultrastructure is 
responsible for the immediate decrease in force production following injury (10, 
16, 41).  In addition to damaging the sarcomeres, lengthening contractions can 
lead to disruption of the plasma membrane and endomysium due to shear forces 
generated during the lengthening contraction (14, 44).  This process of 
sarcomere and membrane damage initiates a response that eventually leads to 
repair of damaged structures and hypertrophy of the damaged muscle fiber.  
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 Cellular Regulation of Muscle Growth and Atrophy.  The nuclei within 
skeletal muscle fibers are arrested at the G1 cell cycle checkpoint and are unable 
to replicate (36).  Following injury to a muscle fiber, the nuclei in the damaged 
area undergo apoptosis (7, 70).  Skeletal muscle stem cells, referred to as 
satellite cells or myoblasts, reside in a space between the sarcolemma and the 
basal lamina (58).  Satellite cells, that normally exist in a quiescent state, become 
activated, migrate to the site of injury, proliferate, and fuse with the damaged 
fiber to repopulate the nuclei lost as a result of injury (24).  Damage to the 
endomysium releases inactive hepatocyte growth factor (HGF) (76).  Reactive 
oxygen species, produced by the nitric oxide synthase (NOS) enzyme, activate 
HGF (77).  Activated HGF binds to the c-met receptor on the plasma membrane 
of satellite cells.  HGF signaling activates the satellite cells from the quiescent 
state and initiates the migration of satellite cells to the site of injury (76).   
 As satellite cells migrate to the site of injury, they also undergo 
proliferation.  The initiation of proliferation is brought on by an increase in the 
expression of the basic helix-loop-helix (bHLH) transcription factor MyoD (24).  
MyoD is one of four members of myogenic regulatory factor (MRF) family, that 
include Myf-5, myogenin and MRF-4.  The MRF family of transcription factors 
initiate the "myogenic program" in these proliferating satellite cells (24).  The 
myogenic program changes the cellular morphology of satellite cells from a 
fibroblastic type morphology to a muscle like morphology (75).  Once in proximity 
of the damaged muscle fiber, satellite cells fuse with each other to form 
multinucleated structures called myotubes.  These myotubes fuse with the 
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existing, damaged muscle fiber and can help bridge the gap between ruptured 
ends of a muscle fiber.  As the myotubes fuse with the muscle fiber, the nuclei 
within the myotubes arrest in G1 (25, 36).  A certain population of satellite cells 
that underwent proliferation do not form myotubes, but instead resume a sub-
basal lamina position and return to quiescence (24).  In addition to satellite cells, 
fibroblasts and immune cells are attracted to the site of injury.  The presence of 
these cells helps to remove cellular debris and repair the ECM.  If there is a 
severe disruption of the ECM, fibroblasts can respond with an overproduction of 
ECM (27).  This overproduction of ECM results in the clinical condition of fibrosis, 
or scar tissue accumulation.  The mechanisms behind the formation of scar 
tissue are of particular interest to clinicians, as this scar tissue is generally 
disruptive to the proper function of muscle tissue and, once formed, is relatively 
permanent (30). 
 Once the myotubes have fused with the damaged muscle fiber, the nuclei 
from these myotubes occupy a centrally located position in the muscle fiber (24, 
52).  While nuclei in an uninjured fiber are typically located just beneath the 
sarcolemma, taking up a central location presumably allows for greater surface 
area contact of the nucleus with ribosomes and endoplasmic reticulum and thus 
enhance the ability of muscle fibers to synthesize new proteins.  During the repair 
stages, the majority of proteins that are synthesized are responsible for repairing 
the damaged fiber (26).  While it is not clear exactly why the nuclei take up a 
subsarcolemmal location after repair, the nuclei do not need as close a direct 
association with endoplasmic reticulum, as mRNA that encodes sarcomeric 
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proteins is trafficked directly to the sarcomere, where translation and processing 
occur (35).  This strategy is likely in place as sarcomeric proteins are relatively 
large, translation at the sarcomere minimizes the need for the muscle fiber to 
have an elaborate protein trafficking system in place.  The location of the nuclei 
within the cytosol therefore provides a way to track the progress of repair in 
skeletal muscle tissue.   
 Molecular Regulation of Muscle Growth and Atrophy.  While the satellite 
cells are undergoing migration, proliferation and fusion, the muscle fiber is 
initiating the underlying processes that are responsible to begin the repair 
process.  Damage to the plasma membrane causes a persistent increase in 
intracellular calcium levels (78).  The influx of calcium initiates the persistent 
activation of sarcomeres distal to the site of injury, and is likely the mechanism 
behind the "muscle spasm" that is observed clinically after a muscle injury.  This 
influx of calcium also activates the proteolytic systems of muscle tissue (5, 29).  
By three days following injury, the plasma membranes of the muscle fibers are 
largely sealed off (64) and calcium homeostasis is restored (5). 
The ubiquitin-proteasome proteolytic system is important in regulating 
skeletal muscle mass and protein turn-over.  Atrogin-1 (MAFbx) is a ubiquitin 
ligase protein expressed in skeletal muscle (20, 32).  Atrogin-1 directs the 
polyubiquination of proteins (8).  Once a protein is tagged with ubiquitin, that 
protein is targeted to the proteasome organelle. The amount of ubiquitin tags on 
a protein appears to be directly related to the speed at which the doomed protein 
is degraded.  Upon reaching the proteasome, the protein is broken down and its 
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constituent amino acids for recycled for use in the synthesis of new proteins.  
The expression of atrogin-1 is regulated by the Forkhead box O (Foxo) family of 
transcription factors (20, 32).  The promoter region of the atrogin-1 gene contains 
binding sites for the Foxo3 transcription factor that acts as a co-activator of 
atrogin-1 transcription (68).  Phosphorylation of Foxo3 by Akt inhibits the ability of 
Foxo3 to enter the nucleus and thus blocks the ability of Foxo3 to act as a 
transcription factor.  
Regulation of Muscle Growth and Atrophy by Myostatin 
Myostatin is a negative regulator of muscle mass (38, 39, 54, 84, 85, 90).  
The myostatin gene consists of three exons, the first two of which encode a 
propeptide, and the third encodes the mature, active form of myostatin (Figure 
1.1).  Compared with MSTN+/+ mice, the MSTN+/- mice used in this study have a 
20% reduction in circulating myostatin levels, and MSTN-/- mice have no 
detectable myostatin (Figure 1.2).  While the masses of the male MSTN+/+, 
MSTN+/- and MSTN-/- mice are similar until 9 months of age, following this time 
point, the masses of the MSTN-/- mice are noticeably greater than MSTN+/+ and 
MSTN+/- mice (Figure 1.3).  The masses of female MSTN+/+, MSTN+/- and MSTN-
/- mice do not differ from one another (Figure 1.3).  Myostatin deficiency 
increases the CSA (cross-sectional area) of muscle fibers from EDL and soleus 
muscles, and also increases the whole muscle CSA (Figure 1.4).  Myostatin 
deficiency does not change the relative myofibrillar protein content of EDL or 
soleus muscles (Figure 1.5). 
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Molecular Signaling Pathways.  Myostatin signal transduction is mediated 
through the activin family of serine/threonine kinase receptors.  Myostatin is 
secreted as a 25 kDa dimer, bound to its 37 kDa propeptide (54).  Upon 
dissociation from its latent complex, myostatin binds the type IIb activin receptor 
(ActRIIB or ACVR2B) (38).  This binding promotes the recruitment and 
phosphorylation of the type Ib activin co-receptor (ActRIB or ACVRB) (38).  The 
activated ActRIIB-ActRIB complex activates Smad2 and Smad3 transcription 
factors, and TAK1, via phosphorylation (Figure 1.6) (62).  Phosphorylation of 
Smad2 and Smad3 allows for these proteins to oligomerize and enter the 
nucleus (57).  Specifically, Smad2 and Smad3 can form homodimers, 
heterodimers and heterotrimers with themselves and an additional transcription 
factor, Smad4 (57).  The Smad oligomers interact with other transcription factors 
and recruit co-activators or co-repressors of gene transcription (57).  The 
activated TAK1 kinase activates the downstream kinases p38 MAPK and Erk1/2 
via MKK3/6 (62, 88).  p38 MAPK and Erk1/2 are able in turn to regulate the 
activity of various transcription factors via phosphorylation.  While the myostatin-
deficient mice have a very clear hypermuscular phenotype, the downstream gene 
targets of myostatin-mediated signal transduction, remain largely unknown.   
Unlike myostatin, IGF-1 (insulin like growth factor-1) is a positive regulator 
of muscle mass.  IGF-1 binds to the IGF-1 receptor that activates PI3K via IRS-1 
(1).  PI3K activates Akt/PKB that activates several downstream transcription 
factors via phosphorylation (1).  Akt appears to regulate muscle mass both by 
promoting satellite cell proliferation and by decreasing protein degradation (20).  
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Akt promotes satellite cell proliferation, at least in part, by increasing the 
expression of MyoD (20).  To inhibit protein degradation, Akt phosphorylates the 
Foxo3 transcription factor that keeps Foxo3 localized in the cytosol (20, 69).  
Foxo3 is a potent activator of atrogin-1, and in the absence of a nuclear localized 
Foxo3 transcription factor, atrogin-1 expression declines (20).  The myostatin and 
IGF-1 pathways can inhibit each other.  Activation of ActRIIB by myostatin blocks 
the IGF-1 mediated phosphorylation of PI3K and Akt (89).  Akt binds and 
prevents the nuclear localization of Smad3 (13).   
Induction of Muscle Atrophy by Myostatin.  The deficiency of myostatin 
results in a profound increase in skeletal muscle mass (38, 39, 54, 84, 85, 90) 
and overexpression of myostatin results in muscle atrophy (66, 91).  While the 
deficiency of myostatin increases protein synthesis (83), it was not known if 
myostatin also increase protein breakdown.  Our preliminary studies of the 
regulation of atrogin-1 by myostatin indicated that, despite no difference in 
relative myofibrillar protein content (Figure 1.5), compared with MSTN+/+ mice, 
the EDL muscles of MSTN-/- mice had a noticeable decrease in ubiquitin tagged 
myosin heavy chain (Figure 1.7A) and a 40% decrease in atrogin-1 expression 
(Figure 1.7C).  For soleus muscles, MSTN-/- mice had only a minor decrease in 
ubiquitin tagged myosin heavy chain (Figure 1.7B) and no difference in atrogin-1 
expression (Figure 1.7D).  The decreased ubiquitination of myosin heavy chain, 
in conjunction with the decrease in atrogin-1 expression, suggests that there is a 
decrease in protein degradation in MSTN-/- EDL muscles.  This may explain why, 
compared with soleus muscles, the deficiency of myostatin leads to a greater 
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relative increase in EDL muscle mass (further discussed in Chapter II). While 
sarcomeric proteins must first be liberated from the sarcomere by calpain 
mediated proteolysis of titin, these results do indicate that myostatin deficiency 
leads to a functional decrease in protein degradation.  Determining the 
expression of the calpain proteases will provide greater insight into this 
mechanism. 
Myostatin increases the expression of atrogin-1 in C2C12 myotubes (53).  
We determined if myostatin could increase the expression of atrogin-1 in primary 
myotubes, and which arm of the myostatin signaling pathway was involved in this 
process.  When  primary myotubes were treated with myostatin, there was a 
dose-dependent increase in atrogin-1 expression (Figure 1.8).  Inhibition of both 
the p38 MAPK and Smad2/3 pathways blocked the myostatin-mediated increase 
in atrogin-1 expression, suggesting that both arms of the myostatin signal 
transduction pathway are important in the regulation of atrogin-1.  While the p38 
MAPK mediated induction of atrogin-1 expression is not clear, Foxo3 can directly 
bind Smad3 to promote gene transcription (22, 69), and the interaction between 
Foxo3 and Smad3 may therefore be necessary for the regulation of atrogin-1 by 
myostatin.  
Methods 
Animals.  All experiments were conducted in accordance with the 
guidelines of the University of Michigan Committee on the Use and Care of 
Animals.  Mice were housed in specific-pathogen-free conditions and were 
provided food and water ad libidum.  The MSTN-/- mice are of a C57Bl/6 
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background and were a kind gift of Dr. Se-Jin Lee (54).  The null MSTN allele 
was generated by replacing a portion of the third exon of the MSTN gene that 
encodes the C-terminal region of the mature myostatin protein with a neo 
cassette (Figure 1.1A).  The genotype of mice was determined by PCR-based 
analysis of DNA samples obtained via tail biopsy (Figure 1.1B). 
ELISA Quantification of Myostatin in Serum.  Approximately 1mL of blood 
was withdrawn from 6 month old male MSTN+/+, MSTN+/-, and MSTN-/- mice, 
allowed to clot and spun at 10,000 × g for 10 minutes to separate serum.  Serum 
was briefly treated with 0.1N HCl to dissociate myostatin from its carrier proteins 
and was subsequently diluted 1:2 in RIPA buffer.  Samples were then subjected 
to sandwich ELISA (R&D Systems) in triplicate. 
Cell Culture.  Satellite cells were isolated from 6 month old male MSTN+/+ 
mice using the methods described by Allen and his colleagues (2).  Mice were 
anesthetized with intraperitoneal injection of Avertin (400 mg/kg) and sacrificed 
by cervical dislocation.  The hindlimb muscles were quickly removed, minced and 
digested in protease solution (1.0 mg/mL of Type XIV Proteinase in PBS, Sigma) 
for 1 hour at 37ºC.  Satellite cells were separated from muscle fiber fragments 
and from tissue debris by differential centrifugation and then plated on fibronectin 
coated 35mm tissue culture plates (BD Biosciences).  Cultures were maintained 
in a humidified environment maintained at 37ºC and 5% CO2.   
Satellite cells were grown in DMEM + 20% FBS + 1% antibiotic-
antimycotic (AbAm) until reaching 80% confluence, at which time the media was 
changed to DMEM + 2% horse serum + 1% AbAm to induce differentiation into 
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myotubes.  Myotubes were maintained in culture for 5 days and then serum 
starved for 24 hours by replacing the differentiation media with DMEM + Insulin-
Transferrin-Selenium Supplement (Invitrogen) + 1% AbAm.  Recombinant murine 
myostatin was produced in NS0 mouse myeloma cells (R & D Systems) and 
dissolved into the starvation media at a final concentration of 250 or 500 ng/mL.  
Stock solutions of the p38 MAPK inhibitor SB-203580 (15) and the Smad2/3 
inhibitor SB-431542 (28) were prepared by dissolving these solid anhydrous 
compounds in DMSO at a concentration of 10mM. SB-203580 and SB-431542 
stock solutions were then added to starvation media containing myostatin and 
0.5% DMSO at a final concentration of 10µM for SB-203580 and 5µM for SB-
431542.  Cells were pretreated with SB-203580 or SB-431542 for 1 hour prior to 
treatment with myostatin for 12 hours. 
Myofibrillar Protein Content.  Myofibrillar proteins were extracted from EDL 
and soleus muscles using the methods of Solaro (71), modified to include the 
addition of Leupeptin (Sigma).  The protein content of the isolated myofibrils was 
determined using a DC Protein Assay (Bio-Rad) and normalized to the wet mass 
of the muscle. 
SDS-PAGE and Immunoblot.  Whole EDL and soleus muscles were 
removed from anesthetized 6 month old MSTN+/+ and MSTN-/- mice, flash frozen 
in liquid nitrogen and stored at -80ºC until use.  Muscles and myotubes were 
homogenized in Laemmli's sample buffer with 1:20 β-mercaptoethanol, 1:20 
protease inhibitor cocktail (Sigma) and 1:40 phosphatase inhibitor cocktail 
(Sigma) and then placed in boiling water for 5 minutes. Protein concentration of 
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the samples was determined using an RC DC Protein Assay (Bio-Rad).  Equal 
amounts of protein were loaded into 4% stacking, 7.5% resolving polyacrylamide 
gels and subjected to electrophoresis. To detect total myosin heavy chain, gels 
were stained with Coomassie Brilliant Blue (Bio-Rad).  To detect ubiquitinated 
myosin heavy chain, proteins were transferred from gels to a 0.45 µm 
nitrocellulose membrane and stained with Ponceau S to verify equal protein 
transfer.  Membranes were blocked using casein (Vector Labs), incubated with 
an HRPO tagged anti-ubiquitin antibody (Santa Cruz) and developed with 
SuperSignal West Dura enhanced chemiluminescent reagents (Pierce 
Biotechnology) and visualized using a FluorChem chemiluminescent 
documentation system (Alpha Innotech). 
RT-qPCR.  RNA was isolated from samples using an RNeasy Fibrous 
Tissue kit (Qiagen) and treated with DNase I.  Poly-A mRNA was reverse 
transcribed using an Omniscript RT system (Qiagen) and oligo(dT)15 primers.  
cDNA was amplified using primers for atrogin-1 (forward: 5'- 
ATTCTACACTGGCAGCAGCA-3'; reverse: 5'- TGTAAGCACACAGGCAGGTC-
3') and β2-microglobulin (forward: 5'-ATGGGAAGCCGAACATACTG-3'; reverse: 
5'-CAGTCTCAGTGGGGGTGAAT-3') using a SYBR Green I PCR system 
(Qiagen) with Uracil DNA Glycosylase (Invitrogen) in an Opticon 2 real-time 
thermal cycler (Bio-Rad). qPCR reactions were conducted in quadruplicate for 
each sample.  C(t) values for atrogin-1 were normalized to β2-microglobulin 
using the 2-ΔΔC(t) method.  β2-microglobulin was selected as a normalizing gene 
based on its stable expression in skeletal muscle tissue (49) and because its 
23 
expression did not differ between groups. The presence of single amplicons from 
qPCR reactions were verified by melting curve analysis as well as 
electrophoresis using a 2% agarose gel.  Genomic DNA contamination was not 
detected in qPCR reactions. 
Statistical Analysis.  Results are presented as means ± SE.  KaleidaGraph 
4.02 software was used to conduct statistical tests.  For ELISA, histology and  
gene expression data from cell culture experiments, differences between groups 
were tested with a one-way ANOVA with α = 0.05.  Fisher’s least significant post 
hoc test was used to identify specific differences when significance was tested.  
For all other data, differences between groups were tested with Student’s t-test 






Figure 1.1.  (A) Structure of wild type and null MSTN alleles.  (B) PCR based 






Figure 1.2.  Mouse models used in the current study.  Picture of (A) whole 
mouse carcasses and (B) hind limb musculature.  (C) Relative myostatin 
concentration in plasma measured by ELISA. N = 6 mice.  *, significantly different 














Figure 1.4.  Muscle fiber CSA distributions. EDL muscles of (A) MSTN+/+, (B) 
MSTN+/- and (C) MSTN-/- mice.  Soleus muscles of (D) MSTN+/+, (E) MSTN+/- and 
(F) MSTN-/- mice. N = 3 muscles from each genotype.  *, significantly different 







Figure 1.5.  Relative myofibrillar protein content of (A) EDL and (B) soleus 
muscles of MSTN+/+ and MSTN-/- mice.  (A) There was no difference between the 
myofibrillar protein content (normalized first to muscle mass, and then to levels in 
MSTN+/+ mice) between MSTN+/+ and MSTN-/- mice for (A) EDL and (B) soleus 












Figure 1.7.  Ubiquitinated myosin heavy chain (Ub-MHC) protein and atrogin-1 
expression from EDL and soleus muscles of MSTN+/+ and MSTN-/- mice.  MSTN-/- 
mice have less Ub-MHC than MSTN+/+ mice in (A) EDL, but there is only a 
minimal difference between genotypes in (B) soleus muscles.  There is a 
decrease in the relative expression of atrogin-1, normalized to β2-microglobulin, 
in (C) EDL muscles of MSTN-/- mice, but no differences in (D) soleus muscles.  N 







Figure 1.8.  Atrogin-1 expression in primary myotubes treated with myostatin.  
Treatment of primary myotubes with myostatin for 12h increases the relative 
expression of atrogin-1, normalized to β2-microglobulin. +, 250ng/mL of 
myostatin. ++, 500ng/mL of myostatin.  *, significantly different from control group 
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Contractile Properties of Extensor Digitorum Longus and Soleus Muscles 




Myostatin is a negative regulator of muscle mass.  The impact of 
myostatin deficiency on the contractile properties of healthy muscles has not 
been determined.  We hypothesized that myostatin deficiency would increase the 
maximum tetanic force (Po), but decrease the specific Po (sPo) of muscles and 
increase the susceptibility to contraction-induced injury.  The in vitro contractile 
properties of EDL and soleus muscles from wild type (MSTN+/+), heterozygous-
null (MSTN+/-) and homozygous-null (MSTN-/-) adult male mice were determined.  
For EDL muscles, the Po of both MSTN+/- and MSTN-/- mice were greater than 
the Po of MSTN+/+ mice.  For soleus muscles, the Po of MSTN-/- mice was greater 
than that of MSTN+/+ mice.  The sPo of EDL muscles of MSTN-/- mice was less 
than MSTN+/+ mice.  For soleus muscles, however, no difference in sPo was 
observed.  Following two lengthening contractions, EDL muscles from MSTN-/- 
mice had a greater force deficit than MSTN+/+ or MSTN+/- mice, whereas no 
differences were observed for the force deficits of soleus muscles.  Myostatin 
deficient EDL muscles had less hydroxyproline, and myostatin directly increased 
type I collagen mRNA expression and protein content.  The difference in the 
response of EDL and soleus muscles to myostatin may arise from differences in 
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the levels of a myostatin receptor, ActRIIB.  Compared with the soleus, the 
amount of ActRIIB was approximately two-fold greater in EDL muscles.  The 
results support a significant role for myostatin not only in the mass of muscles, 
but also in the contractility and the composition of the ECM of muscles. 
Introduction 
Myostatin (GDF-8) is a member of the transforming growth factor-beta 
(TGF-β) family of cytokines and functions as a negative regulator of skeletal 
muscle mass.  Inactivation of the myostatin genes and post-natal inhibition of 
myostatin both result in significant increases in skeletal muscle mass (4, 5, 21, 
42, 47, 65, 68, 69).  Systemic and skeletal muscle specific overexpression of 
myostatin induce skeletal muscle atrophy (52, 71).  The Belgian Blue and 
Piedmontese breeds of cattle have a mutated form of the myostatin gene and are 
characterized by larger skeletal muscles than other breeds (20, 24).  At the time 
of birth, a human child with apparent null mutations in his myostatin genes had a 
thigh muscle volume two-fold greater in size than ten age-matched controls (54).  
The child's mother, who is heterozygous for the mutation, was also reported to be 
hypermuscular (54).   
Myostatin circulates through the blood in a latent form bound to its 
propeptide and to follistatin (2).  The myostatin gene (MSTN) encodes a 
precursor protein that undergoes proteolytic processing to generate a propeptide 
and a mature myostatin dimer (67).  The propeptide binds myostatin 
noncovalently and inhibits the bioactivity of myostatin (42, 57, 67).  Cleavage of 
the propeptide by the BMP-1/tolloid family of metalloproteinases results in the 
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liberation and activation of myostatin (67).  Activated myostatin binds to the 
activin type IIB (ActRIIB) and IB (ActRIB) receptors to initiate the Smad2/3 and 
p38 MAPK intercellular signal transduction cascades (29, 46, 50, 70).  Myostatin 
appears to regulate skeletal muscle mass, at least in part, by inhibiting the 
proliferation, differentiation and self-renewal of myoblasts (28, 39, 56, 58).  Type 
II muscle fibers appear to be more responsive to the myostatin signaling pathway 
than type I muscles, but the mechanism responsible for this difference is 
unknown (10, 37, 41, 43).  
The inhibition of myostatin may be useful in the treatment of muscle 
injuries and muscle wasting diseases by improving the contractile properties of 
muscle (17, 26, 45, 53, 55, 59, 61).  Compared with wild type mice, myostatin 
deficient mice have increased bite force (9) and gross grip strength (65).  
Treating mdx mice with an antibody against myostatin increased the maximum 
tetanic force (Po) of EDL muscles, but did not change the specific maximum 
tetanic force (sPo) (4).  When mdx mice were treated with the propeptide of 
myostatin, both the Po and sPo of EDL muscles increased (5).   
Myostatin may also be useful in treating muscle injuries and disease by 
regulating the collagen accumulation and scar tissue formation in the 
extracellular matrix (ECM) (17, 45).  In addition to enhancing the contractile 
properties of dystrophic muscle, the deficiency of myostatin decreased the 
accumulation of scar tissue and ECM of mdx mice (4, 5, 63).  Type I collagen is a 
major component of muscle ECM (31).  The transcripts of two separate genes, 
col1α1 and col1α2, are used to synthesize the collagen I precursor molecule, 
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procollagen I.  Procollagen I is secreted into the ECM where it undergoes 
cleavage and assembly to form mature collagen I (27).  TGF-β has a well 
established role as a positive regulator of type I collagen protein synthesis via the 
Smad2/3 and p38-MAPK signaling pathways (reviewed in (60)).  As myostatin is 
a member of the TGF-β family of cytokines and utilizes similar signal transduction 
pathways as TGF-β (29, 46, 50, 70), myostatin may have a direct role in the 
regulation of the type I collagen content of skeletal muscle ECM.   
While a few studies have examined the effects of myostatin deficiency on 
the contractile properties and ECM of dystrophic muscles (4, 5, 63), how 
myostatin deficiency impacts on healthy, non-dystrophic muscle is unknown.  
The overall aim of this study was to determine the effect of myostatin deficiency 
on the contractile properties, susceptibility to contraction-induced injury and 
collagen composition of skeletal muscle tissue.  As increases in Po due to 
hypertrophy of muscle fibers often results in a corresponding decrease in sPo 
(15, 25, 30), we hypothesized that a deficiency of myostatin would increase the 
Po, but decrease the sPo.  Based upon the observations that myostatin deficiency 
decreased the ECM accumulation in dystrophic muscle (4, 5, 63), and the 
similarities between the myostatin and TGF-β signal transduction pathways (29, 
46, 50, 70), we formed the hypothesis that myostatin deficient mice would have 
less muscle ECM and that myostatin would directly increase type I collagen 
expression in skeletal muscle tissue.  If these assumptions proved to be correct, 
we hypothesized that the deficiency of myostatin would increase the force deficits 
of muscles following a protocol of damaging lengthening contractions.  
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Methods 
Animals.  All experiments were conducted in accordance with the 
guidelines of the University of Michigan Committee on the Use and Care of 
Animals.  Mice were housed in specific-pathogen-free conditions and fed food 
and water ad libidum.  MSTN-/- mice of a C57BL/6 background were a generous 
gift of Dr. Se-Jin Lee.  The MSTN null allele was generated by replacing the 
portion of the third exon of the MSTN gene that encodes the C-terminal region of 
the mature myostatin protein with a neo cassette (42).  Male MSTN-/- mice were 
crossed with MSTN+/+ C57BL/6 female mice to generate an F1 MSTN+/- 
generation.  The F1 generation was backcrossed to obtain an F2 generation 
containing all three genotypes.  F2 male mice 10 - 12 months of age were used 
in this study.  The genotype of mice was determined by PCR-based analysis of 
genomic DNA samples obtained via tail biopsy.  The MSTN wild type allele was 
detected using a set of primers that generate a 247 bp amplicon from the third 
exon of the MSTN gene, and the MSTN null allele was detected using a set of 
primers that generate a 192 bp amplicon from the neo cassette that replaced the 
third exon of the MSTN gene.  Amplicons from PCR reactions were separated on 
a 2% agarose gel.   
Operative Procedure.  Mice were anesthetized with intraperitoneal 
injection of Avertin (400 mg/kg).  Additional doses were provided as required to 
maintain a deep anesthesia throughout the experiment.  The EDL and soleus 
muscles were removed from both the left and right legs of each mouse.  Muscles 
used for fiber counts, hydroxyproline, histochemistry or protein analysis were 
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flash frozen in liquid nitrogen and stored at -80°C until use.  A 5-0 silk suture was 
tied to the proximal and distal tendons of muscles used in the contractile 
properties experiments.  These muscles were placed immediately in a bath that 
contained Kreb's mammalian Ringer solution with 0.25 mM tubocurarine 
chrloride. The bath was maintained at 25°C and the solution was bubbled with 
95% O2 and 5% CO2 to stabilize pH at 7.4.  Following the removal of muscles, 
mice were euthanized with an overdose of anesthetic and induction of a 
pneumothorax.       
Fiber Counts of Muscles.  To determine the number of fibers present in 
muscles, the extracellular matrices of muscles were digested as described (38).  
Briefly, muscles were placed in a 15% HNO3 solution overnight at room 
temperature.  Following digestion, the HNO3 solution was replaced with 
phosphate buffered saline.  Individual muscle fibers were teased apart from 
bundles and counted under a dissecting microscope.  The lengths of forty 
individual fibers per muscle were measured using digital calipers.      
Measurement of Maximum Isometric Tetanic Force.  Each muscle was 
immersed in the bath solution and the distal tendon was attached to a servo 
motor (model 305B, Aurora Scientific, Aurora, ON).  The proximal tendon was 
attached to a force transducer (model BG-50, Kulite Semiconductor Products, 
Leonia, NJ).  The attachment of tendons to the servo motor and force transducer 
occurred just distal to the myotendinous junctions so that the impact of the 
tendon on the measurement of contractile properties was minimized.  Muscles 
were stimulated by square pulses delivered by two platinum electrodes 
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connected to a high-power biphasic current stimulator (model 701B, Aurora 
Scientific).  An IBM-compatible personal computer and custom designed 
software (LabVIEW 7.1, National Instruments, Austin, TX) controlled electrical 
pulse properties and servo motor activity and recorded data from the force 
transducer.  The voltage of pulses was increased and muscle length (Lo) was 
subsequently adjusted to the length that resulted in maximum twitch force (Pt) 
(6).  The Lo was measured with digital calipers.  Muscles were held at Lo and 
subjected to trains of pulses to generate an isometric contraction.  Pulse trains 
were 300 ms for EDL muscles and 900 ms for soleus muscles.  Stimulus 
frequency was increased until the Po was achieved (6).  The general shape of the 
force traces during twitch and isometric contractions were not different between 
the three genotypes of mice for EDL and soleus muscles, respectively.  The sPo 
was determined by dividing Po by the cross sectional area (CSA).  Following nitric 
acid digestion, both EDL and soleus muscles showed no difference in the ratio of 
fiber lengths to whole muscle lengths among any of the three genotypes.  
Therefore the Lf/Lo ratios of 0.44 for EDL muscles and 0.70 for soleus muscles 
were used to calculate Lf (6).  The physiological CSA of muscles was determined 
by dividing the mass of the muscle by the product of Lf and 1.06 g/cm3, the 
density of mammalian skeletal muscle.         
Contraction-Induced Injury.  Following measurement of Pt and Po, a 
mechanical injury to muscles was produced by two 40% lengthening contractions 
(7, 11, 14).  Muscles were stimulated and held at Lo for 100 ms for EDL muscles 
and 300 ms for soleus muscles to allow muscles to develop Po.  Following the 
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isometric contraction, muscles were stretched through a 40% strain relative to Lf.  
A 40% strain of the EDL plantarflexes the ankle by 12º and the soleus dorsiflexes 
by 16º.  The velocity of the stretch was 1 Lf/s.  The total time of stimulation was 
500 ms.  Following stimulation, muscles were returned to Lo, remained quiescent 
for 1 min, then were subjected to a second 40% strain.  Following 1 min of rest 
the Po was measured.  The general shape of the force traces during lengthening 
contractions were not different for any of the three genotypes of mice.  The 
average force produced during a stretch was calculated by integrating the force-
time curve and dividing this value by the duration of the stretch.  Work was 
calculated by multiplying the average force produced during a stretch by the 
length of the displacement and normalized by the wet mass of the muscle.   
Measurement of Lengths of Tibias.  Hindlimbs from euthanized mice were 
stripped of gross muscle and connective tissue and placed in 20% hydrogen 
peroxide at 55°C overnight to remove remaining soft tissue.  Photographic 
images of tibias were analyzed with ImageJ (version 1.34, NIH, Bethesda, MD) to 
determine length.      
Hydroxyproline Assay.  Hydroxyproline content of muscles was measured 
as described by Woessner (66).  Muscles were dried for 90 min at 110ºC and 
hydrolyzed in 500 µL of 6 M hydrochloric acid for 3.5 hours.  The hydrolysate was 
neutralized with an equal volume of 6 M sodium hydroxide.  Known amounts of 
purified L-hydroxyproline (Sigma, St. Louis, MO) were used to construct a 
standard curve.  Samples were assayed in triplicate using a Genios plate reader 
(Tecan, Mannedorf, Switzerland) at an absorbance of 560 nm.    
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Histology.  Muscles were cryosectioned at their mid-belly and stained with 
Masson's Trichrome.  The areas of 100 muscle fibers randomly selected from 
sections of three muscles of each of the three genotypes were measured using 
ImageJ.    
ActRIIB Immunoblot.  Muscles that did not undergo assessments of the 
contractile properties were homogenized in cold Laemmli's sample buffer with 
1:20 β-mercaptoethanol and 1:20 protease inhibitor cocktail (Sigma) and then 
placed in boiling water for 5 minutes.  Protein concentration of the samples was 
determined using an RC DC Protein Assay (Bio-Rad, Hercules, CA).  Equal 
amounts of protein were loaded into two 4% stacking, 7.5% separating 
polyacrylamide gels and subjected to electrophoresis.  To verify equal protein 
loading, gels that were not used in immunoblotting were stained with Coomassie 
Brilliant Blue (Bio-Rad).  Proteins were transferred to a 0.45 µm nitrocellulose 
membrane and stained with Ponceau S to verify equal protein transfer.  
Membranes were blocked using casein and an avidin-biotin blocking kit (Vector 
Labs, Burlingame, CA), rinsed and incubated with a biotinylated monoclonal 
antibody against ActRIIB (R & D Systems, Minneapolis, MN) and an avidin-
HRPO conjugate (Vector Labs).  Membranes were developed with SuperSignal 
West Dura enhanced chemiluminescent reagents (Pierce Biotechnology, 
Rockford, IL) and visualized using a chemiluminescent documentation system 
(Bio-Rad).   
Satellite Cell Isolation and Culture.  Satellite cells were isolated from adult 
male MSTN+/+ mice as described by Allen and his colleagues (1).  Mice were 
47 
anesthetized with intraperitoneal injection of Avertin (400 mg/kg) and sacrificed 
by cervical dislocation.  The hindlimb muscles were quickly removed, minced and 
digested in protease solution (1.25 mg/mL of Pronase E in PBS, Sigma) for 1 
hour at 37ºC.  Satellite cells were separated from muscle fiber fragments and 
from tissue debris by differential centrifugation and then plated on fibronectin 
coated 60mm tissue culture plates (BD Biosciences, San Jose, CA).  Cultures 
were maintained in a humidified environment maintained at 37ºC and 5% CO2.  
Satellite cells were grown in DMEM + 20% FBS + 1% antibiotic-antimycotic 
(AbAm) until reaching 80% confluence, at which time the media was changed to 
DMEM + 2% horse serum + 1% AbAm to induce differentiation into myotubes.   
RT-qPCR.  Myotubes were treated with different concentrations of 
recombinant murine myostatin (R & D Systems, Minneapolis, MN) in DMEM + 
1% AbAm for 2 hours.  RNA was isolated from myotubes using an RNeasy Mini 
kit (Qiagen, Valencia, CA), treated with DNase I and reverse transcribed using an 
Omniscript RT kit (Qiagen) and oligo(dT)15 primers.  cDNA was amplified using 
primers for col1α2 (forward: 5'-CCAGCGAAGAACTCATACAGC-3'; reverse: 5'-
GGACACCCCTTCTACGTTGT-3') and β2-microglobulin (forward: 5'-
ATGGGAAGCCGAACATACTG-3'; reverse: 5'-CAGTCTCAGTGGGGGTGAAT-
3') using a SYBR Green I PCR system (Qiagen) with Uracil DNA Glycosylase 
(Invitrogen) in an Opticon 2 real-time thermal cycler (Bio-Rad). qPCR reactions 
were conducted in triplicate for each sample.  C(t) values for col1α2 were 
normalized to β2-microglobulin (β2m) using the 2-ΔΔC(t) method (32).  β2m was 
chosen as a housekeeping gene based on its stable expression in skeletal 
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muscle tissue (35) and because β2m expression did not differ between treatment 
groups.  The presence of single amplicons from qPCR reactions were verified by 
melting curve analysis as well as electrophoresis using a 2% agarose gel.  
Primers for col1α2 generate a 105 bp amplicon from exons 46 and 47 of the 
col1α2 gene.  Intron 46 - 47 of the col1α2 gene is 320 bp which would allow us to 
detect the presence of genomic DNA in qPCR reactions using gel 
electrophoresis.  Genomic DNA contamination was not detected in qPCR 
reactions. 
Procollagen I Immunoblot.  Myotubes were treated with different 
concentrations of recombinant murine myostatin (R & D Systems) in DMEM + 1% 
AbAm for 8 hours, rinsed with PBS and 0.5M EDTA, scraped and homogenized 
in Laemmli's sample buffer with 1:20 β-mercaptoethanol and 1:20 protease 
inhibitor cocktail (Sigma) and subsequently placed in boiling water for 5 minutes.  
Protein concentration, electrophoresis and blotting occurred as described above.  
Membranes were blocked in 10% powdered milk, rinsed and incubated with a 
polyclonal antibody against procollagen I (Santa Cruz Biotechnology, Santa 
Cruz, CA) and an HRPO conjugated secondary antibody (Pierce Biotechnology), 
and developed as described above.  Following detection of procollagen I, 
membranes were stripped and reprobed using a monoclonal antibody against β-
tubulin (Developmental Studies Hybridoma Bank, Iowa City, IA). 
Statistical Analyses.  Results are presented as mean ± SEM.  
KaleidaGraph 4.02 software (Synergy Software, Reading, PA) was used to 
conduct statistical analyses.  Differences between groups were tested using a 
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one-way ANOVA with α=0.05.  Fisher's LSD post-hoc test was used to identify 
specific differences when significance was detected.          
Results 
Morphology.  The body mass, body length, tibial length, muscle mass, 
absolute numbers of fibers per muscle, fiber areas, Lo, Lf, and CSA values of 
EDL and soleus muscles from each of the three groups of mice are shown in 
Table 2.1.  Although no differences were observed for body masses or body 
lengths of the MSTN+/+, MSTN+/- or MSTN-/- mice, the mean mass of the EDL 
muscles of MSTN-/- mice was 66% greater than that of the MSTN+/+ mice and 
51% greater than that of the MSTN+/- mice.  For MSTN-/- mice, the mass of the 
soleus was 36% greater soleus muscle mass than that of the MSTN+/+ mice.   
Conflicting reports have been published regarding the role of myostatin in 
determining the number of fibers per muscle (21, 36, 42, 47, 51, 68, 69).  Each of 
these reports counted the number of muscle fibers present in a cross section of 
muscle.  The counting of the number of fibers present in a cross section of a 
muscle does not necessarily provide an accurate indication of the total number of 
fibers present in that muscle (38).  To address this issue, the absolute number of 
fibers in muscles from MSTN+/+, MSTN+/- and MSTN-/- mice were counted.  The 
EDL muscles of MSTN-/- mice had 60% more muscle fibers than MSTN+/+ mice 
and 39% more fibers than MSTN+/- mice, and the MSTN+/- mice had 16% more 
fibers than MSTN+/+ mice (Table 2.1).  For soleus muscles, MSTN-/- mice had 
31% more fibers than MSTN+/+ mice and 9% more than MSTN+/- mice, and the 
MSTN+/- mice had 20% more fibers than MSTN+/+ mice (Table 2.1).   
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The mean fiber areas and CSA of EDL muscles of MSTN+/- and MSTN-/- 
mice were greater than MSTN+/+ mice.  For soleus muscles, the mean fiber areas 
and CSA of MSTN-/- mice were greater than MSTN+/+ mice (Table 2.1).    
The EDL and soleus muscles of mice both originate on the proximal tibia 
and run the entire length of the tibia before inserting on the phalanges or 
calcaneus, respectively.  No differences in the lengths of tibias of MSTN+/+, 
MSTN+/- and MSTN-/- mice were observed (Table 2.1).  Furthermore, the Lo and 
Lf values of EDL and soleus muscles, respectively, were not different among the 
three genotypes.   
Collagen Content of Muscles.  The amino acid hydroxyproline makes up 
~14% of the dry mass of fibrillar collagens (44) and is commonly used as an 
indicator of collagen content.  The relative hydroxyproline content of EDL 
muscles of MSTN-/- was 75% less than MSTN+/+ mice (Table 2.1 and Figure 2.1).  
MSTN+/- mice had 59% less hydroxyproline than MSTN+/+ mice.  For soleus 
muscles, no difference was observed  for the relative amounts of hydroxyproline 
amongst the three genotypes (Table 2.1 and Figure 2.1).         
Myostatin Mediated Type I Collagen Synthesis.  The marked decrease in 
the collagen content of the EDL muscles from myostatin deficient mice lead us to 
hypothesize that myostatin induces the expression of type I collagen in muscle 
tissue.  We found a dose dependent increase in col1α2 expression (Figure 2.2) 
and procollagen I protein content (Figure 2.2) of primary myotubes treated with 
myostatin.  Similar results were observed in C2C12 myotubes and primary 
fibroblasts isolated from mouse tendon (data not shown). 
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Contractile Properties.  Myostatin deficiency had a more profound impact on the 
contractile properties of EDL muscles than soleus muscles (Table 2.2 and Figure 
2.3).  The Po of MSTN-/- mice was 34% greater than the Po of MSTN+/+ mice and 
19% greater than the Po of MSTN+/- mice.  MSTN+/- mice had a 13% greater Po 
than MSTN+/+ mice.  When Po was normalized by the CSA, MSTN-/- mice had an 
18% lower value for sPo than either MSTN+/+ or MSTN+/- mice.  For soleus 
muscles, the Po of MSTN-/- mice was 30% greater than MSTN+/+ mice, but the 
values for sPo were not different.   
Contraction-Induced Injury.  During lengthening contractions, the average 
force developed by EDL muscles was not different, but compared with MSTN+/+ 
mice, the work done to lengthen the muscles was 12% and 37% less for MSTN+/- 
and MSTN-/- mice, respectively (Table 2.3), indicating a decrease in the stiffness 
of these muscles.   After the lengthening contraction protocol (LCP), muscles 
from MSTN-/- mice had a force deficit that was 15% greater than MSTN+/+ mice 
(Table 2.3 and Figure 2.4).  During stretches of soleus muscles, the average 
force developed by MSTN-/- mice was approximately 18% greater than that of 
MSTN+/+ mice.  During lengthening contractions of soleus muscles, no 
differences in the work done to stretch the muscles were observed.  Following 
the LCP, the force deficits of soleus muscles were not different.   
ActRIIB Content of EDL and Soleus Muscles.  The deficiency of myostatin 
had a more profound impact on the morphological and contractile properties of 
EDL muscles than soleus muscles.  Since myostatin appears to act systemically 
(71), the difference in the amount of ActRIIB present in EDL and soleus muscles 
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was determined.  Compared with soleus muscles, the amount of ActRIIB was 
greater in EDL muscles (Figure 2.5).   
Discussion 
The Po of skeletal muscle can be increased by either hypertrophy of 
existing fibers or by hyperplasia.  In either case, as whole muscle CSA increases, 
the angle of pennation of muscle fibers (θ) also increases (38).  The transmission 
of the force developed by single muscle fibers from tendon to tendon along the 
line of tension development of the muscle is proportional to the cosine of θ.  As θ 
increases from 0º to 90º, the cosine of θ decreases from 1 to 0.  Therefore, as a 
muscle undergoes hypertrophy or hyperplasia, the net force per CSA is expected 
to decrease.  Our hypothesis that myostatin deficiency would increase the Po but 
decrease the sPo of muscles is supported by the observations of the contractile 
properties of the EDL muscles of MSTN-/- mice.  In contrast, for soleus muscles, 
the complete deficiency of myostatin increased the Po less than that of the EDL 
muscle and had no effect on the sPo.  Furthermore, EDL muscles of MSTN+/- 
mice displayed a  greater Po than MSTN+/+ mice, but showed no change in sPo.  
While θ was not measured directly, using a model of muscle architecture that 
estimates θ based upon the number of fibers in a muscle, Lf, Lo and fiber areas 
(38), compared with MSTN+/+ mice, we estimate that MSTN-/- mice had a 38% 
greater θ for EDL muscles, and a 17% greater θ for soleus muscles, respectively.  
The greater increase in θ for EDL than soleus muscles may explain the observed 
decrease in sPo for EDL muscles and the lack of change in sPo for soleus 
muscles.  In terms of the magnitude of the increases in muscle CSA, mass and 
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Po, a threshold appears to exist for initiating a decrease in sPo, wherein large 
increases in muscle CSA, mass and Po initiate decreases in sPo, whereas with 
small increases, sPo does not change.   
Following contraction-induced injury to muscles, the immediate force 
deficit results from the mechanical disruption of the ultrastructure of sarcomeres 
(8, 18, 33, 34).  The magnitude of this force deficit is a function of strain and the 
work done to stretch the contractile component (CC) of muscle (8).  The 
aponeurosis (intramuscular tendon) and the tendon, composed chiefly of type I 
and III collagen (12, 22, 27), form the series elastic component (SEC) of muscle 
(23).  A positive correlation exists between the collagen content and stiffness of a 
muscle (16, 19, 48).  During a lengthening contraction, the total displacement of 
the muscle is the sum of the displacement of the CC and the SEC, therefore 
displacement of the SEC protects the CC from contraction-induced injury.  During 
a  lengthening contraction, the protection afforded to the CC by the SEC 
increases as the displacement of the SEC relative to the CC increases.  Despite 
this potential for protection, if the strain and work done during a lengthening 
contraction are great enough, the SEC can become damaged and no longer 
provide protection for the CC.  Consequently, an advantageous arrangement for 
a muscle is to have an SEC with a stiffness that allows for a moderate amount of 
displacement during a lengthening contraction, but not too compliant as to 
become damaged during a lengthening contraction.  Our results suggest that for 
EDL muscles, the complete deficiency of myostatin decreases the stiffness of the 
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SEC in such a way that the susceptibility to contraction-induced injury is 
increased.   
  The effect of myostatin deficiency on the structure and function of EDL 
and soleus muscles was quite different.  Compared with the content of the 
primary myostatin receptor, ActRIIB, in the soleus muscles of MSTN+/+ mice, the 
content in the EDL muscles was ~ two-fold greater.  The greater quantity of 
ActRIIB in the EDL muscles of MSTN+/+ mice appeared to make the EDL 
muscles more responsive than soleus muscles to the presence of myostatin.  
Consequently, with the absence of myostatin in the MSTN-/- mice, the EDL 
muscles experience a much greater relative increase in mass and number of 
fibers than experienced by the soleus muscles.   
The treatment of muscle injuries and disease often involves a two-pronged 
therapeutic regimen of improving the strength of muscle and decreasing the 
formation of collagenous scar tissue (13, 49).  Much of the interest behind the 
potential use of myostatin inhibitors is the ability of these inhibitors to enhance 
the regeneration of skeletal muscle and also decrease the accumulation of scar 
tissue in murine models of muscle injuries and disease (17, 40, 45, 61-63).  
Myostatin inhibitors may therefore be a useful therapeutic adjunct to traditional 
athletic training and physical therapy by directly improving contractility and 
decreasing fibrosis.  The enhanced regenerative capacity of myostatin-deficient 
muscle is likely due to an increase in satellite cell activity, as myostatin is a 
negative regulator of satellite cell proliferation and migration (28, 39, 40, 56, 58, 
62).  The increased satellite cell activity produced by the deficiency of myostatin 
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does not explain how myostatin deficiency decreases the fibrosis normally 
present in dystrophic muscle (4, 5, 63) and following snake venom-induced 
muscle injury (40, 62).  The decreased content of collagen in otherwise healthy 
myostatin-deficient muscles, along with the observation that myostatin increases 
directly the expression of type I collagen in cultured muscle tissue, suggest a 
direct role for myostatin in the signal transduction pathways that regulate the 
collagen content of the ECM of skeletal muscle tissue. 
Pharmaceutical inhibition of myostatin likely suppresses, but does not 
eliminate myostatin signaling completely.  The haploinsufficient MSTN+/- mouse 
provides a useful model for the investigation of the effects of partial suppression 
of myostatin signaling.  In the present study, compared with their MSTN+/+ 
littermates, the EDL muscles of MSTN+/- mice developed a greater Po, but unlike 
the MSTN-/- mice had no difference in sPo or force deficit after injury.  The 
collagen content and stiffness of the EDL muscles of MSTN+/- mice was less than 
that of MSTN+/+ mice, but this did not increase the susceptibility of these muscles 
to contraction-induced injury.  Such a decrease in the stiffness of muscle might 
be beneficial in the treatment of diseases that involve severe muscle fibrosis, 
such as Duchenne muscular dystrophy (DMD).  Patients with DMD suffer from 
respiratory insufficiency due to impaired contractility of the diaphragm muscle 
and to the increased stiffness of the diaphragm muscle (3, 64).  Therefore, partial 
inhibition of myostatin may provide a useful treatment for fibrotic muscle diseases 
through an increase in the contractile forces and a decrease in the stiffness of 
the muscles.    
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Figure 2.1.  Relative hydroxyproline content of EDL (A) and soleus (B) muscles 
from MSTN+/+, MSTN+/- and MSTN-/- mice.  (A) Compared with MSTN+/+ mice, the 
amount of hydroxyproline per mg of dry EDL muscle mass was less for MSTN+/- 
and MSTN-/- mice.  (B) There was no difference in the amount of hydroxyproline 
per mg of dry soleus muscle mass between MSTN+/+, MSTN+/- and MSTN-/- mice.  
Values are means ± SE.  N = 5 muscles per genotype.  *Significantly different 








Figure 2.2.  Myostatin increases (A) col1α2 expression and (B) procollagen I 
content of primary skeletal muscle myotubes.  (A) RT-qPCR: Myostatin increases 
the expression of col1α2 normalized to β2m in a dose-dependant fashion.  
Values are means ± SE.  *Significantly different from the 0 ng/mL group at P < 
0.05.  #Significantly different from the 10ng/mL group at P < 0.05.  (B) 
Immunoblot: Myostatin increases the procollagen I protein content of myotubes in 








Figure 2.3.  Force values for EDL muscles (A, B) and soleus muscles (C,D) from 
MSTN+/+, MSTN+/- and MSTN-/- mice.  (A) The Po of EDL muscles of MSTN-/- 
mice is greater than the Po of MSTN+/+ and MSTN+/- mice.  (B) When Po is 
normalized to CSA, the sPo of EDL muscles of MSTN-/- mice is less than the sPo 
of MSTN+/+ and MSTN+/- mice.  (C) The Po of soleus muscles of MSTN-/- mice is 
greater than the Po of MSTN+/+ and MSTN+/- mice.  (D) When Po is normalized to 
CSA, there is no difference in sPo of soleus muscles.  Values are means ± SE.  N 
= 6 muscles per genotype.  *Significantly different from MSTN+/+ at P < 0.05.  








Figure 2.4.  Force deficits following contraction-induced injury to EDL muscles 
(A) and soleus muscles (B).  (A) Muscles from MSTN-/- mice had a force deficit 
that was greater than MSTN+/+ mice after the first lengthening contraction, and a 
force deficit that was greater than MSTN+/+ and MSTN+/- mice after the second 
lengthening contraction.  (B) There was no difference in the force deficits 
between soleus muscles following the lengthening contractions.  LC = 
Lengthening contraction.  Values are means ± SE.  N = 6 muscles per genotype.  
*Significantly different from MSTN+/+ at P < 0.05.  #Significantly different from 








Figure 2.5.  ActRIIB protein content of EDL and soleus muscles from MSTN+/+ 
mice.  Compared with soleus muscles, the amount of ActRIIB protein is greater in 
EDL muscles (immunoblot).  Sarcomeric myosin proteins are shown as loading 

































 MSTN+/+ MSTN+/- MSTN-/- 
Body Mass (g) 32.39±1.32 36.63±1.11 35.01±1.27 
Body Length (mm) 93.33±0.53 95.00±0.59 92.75±0.92 
Tibia Length (mm) 17.91±0.10 17.74±0.13 18.07±0.15 
EDL Muscles    
Wet Mass (mg) 11.62±0.29 12.82±0.25* 19.32±0.52*# 
Fibers per muscle 1462±12 1693±58* 2351±87*# 
Fiber area (µm2) 1231.12±28.64 1315.38±24.55* 1512.14±29.00*# 
Lo (mm) 13.13±0.43 12.78±0.22 13.38±0.23 
Lf (mm) 5.78±0.19 5.63±0.10 5.89±0.10 
CSA (mm2) 1.90±0.04 2.15±0.05* 3.10±0.07*# 
Hyp / Muscle Mass (µg/mg) 1.90±0.14 0.77±0.09* 0.47±0.08* 
Soleus Muscles    
Wet Mass (mg) 10.45±0.44 11.97±0.78 14.22±0.73* 
Fibers per muscle 985±37 1185±33* 1292±34*# 
Fiber area (µm2) 1148.99±20.89 1162.28±20.66 1316.45±36.12*# 
Lo (mm) 12.42±0.30 12.55±0.25 12.98±0.46 
Lf (mm) 8.82±0.21 8.91±0.18 9.22±0.33 
CSA (mm2) 1.12±0.06 1.27±0.07 1.45±0.03* 
Hyp / Muscle Mass (µg/mg) 0.71±0.10 0.61±0.09 0.54±0.09 
 
Table 2.1.  Anatomical properties of animals.  Values are means ± SE.  N = 12 
for tibia length and body length.  N = 300 fibers from 3 muscles for each 
genotype.  N = 5 muscles per genotype for fibers per muscle and hydroxyproline.  
N = 6 muscles per genotype for all other values.  *Significantly different from 





 MSTN+/+ MSTN+/- MSTN-/- 
EDL Muscles    
Pt (mN) 110.78±4.84 136.76±12.33 160.87±8.07* 
sPt (mN/mm2) 58.20±1.75 63.27±5.10 52.25±3.38 
TTPT (ms) 23.68±2.80 20.91±1.32 23.86±2.46 
½RT (ms) 22.56±1.48 20.80±1.02* 15.51±0.25*# 
dP/dt (mN/ms) 13.07±0.05 15.64±1.29 19.00±1.24*# 
Po (mN) 461.19±14.69 520.53±18.48* 616.93±17.10*# 
sPo (mN/mm2) 243.32±10.04 242.12±8.22 199.86±7.37*# 
Soleus Muscles    
Pt (mN) 47.12±2.78 60.43±5.00 65.52±5.85* 
sPt (mN/mm2) 42.08±1.90 47.51±2.30 45.06±3.81 
TTPT (ms) 40.61±4.68 32.41±0.99 27.38±3.75 
½RT (ms) 50.10±5.42 47.55±2.13 37.57±1.92 
dP/dt (mN/ms) 4.20±0.21 4.91±0.33 6.08±0.80 
Po (mN) 295.84±7.49 324.94±18.52 385.06±17.57*# 
sPo (mN/mm2) 265.81±10.10 257.15±6.34 264.84±8.50 
 
Table 2.2.  Contractile Properties of EDL and Soleus Muscles.  Values are 
means ± SE.  N = 6 muscles per genotype.  Pt = peak twitch force; sPt = specific 
Pt; TTPT = time to peak twitch tension; ½RT = half-relaxation time; dP/dt = 
maximum rise in tension.  *Significantly different from MSTN+/+ at P < 0.05.  





 MSTN+/+ MSTN+/- MSTN-/- 
EDL Muscles    
Stretch 1    
  Average Force (mN) 648.07±8.21 644.48±15.74 664.56±8.63 
  Work (J/kg) 129.00±3.66 113.05±1.85* 81.31±2.65*# 
  Force Deficit (% of Pre-injury Po) 15.74±0.81 18.19±2.78 24.14±3.03* 
Stretch 2    
  Average Force (mN) 631.03±8.43 632.78±14.93 651.86±9.00 
  Work (J/kg) 125.58±3.39 111.01±1.76* 79.76±2.65*# 
  Force Deficit (% of Pre-injury Po) 30.10±1.71 29.59±2.46 45.23±6.52*# 
Soleus Muscles    
Stretch 1    
  Average Force (mN) 509.53±26.93 537.37±33.60 620.89±28.49* 
  Work (J/kg) 173.21±11.68 160.60±5.56 161.15±5.39 
  Force Deficit (% of Pre-injury Po) 18.21±3.63 19.18±4.38 18.60±2.52 
Stretch 2    
  Average Force (mN) 455.83±14.49 480.13±29.67 569.29±31.98*# 
  Work (J/kg) 154.89±8.35 143.33±3.96 147.60±6.21 
  Force Deficit (% of Pre-injury Po) 20.68 ± 4.93 20.21 ± 3.45 25.08 ± 3.76 
 
Table 2.3.  Mechanical Injury of EDL and Soleus Muscles.  Values are means ± 
SE.  N = 6 muscles per genotype.  *Significantly different from MSTN+/+ at P < 





1. Allen RE, Temm-Grove CJ, Sheehan SM, and Rice G. Skeletal muscle 
satellite cell cultures. Methods Cell Biol 52: 155-176, 1997. 
2. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, 
and Patel K. Follistatin complexes Myostatin and antagonises Myostatin-
mediated inhibition of myogenesis. Dev Biol 270: 19-30, 2004. 
3. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora 
M, Cornelio F, Morandi L, and Mantegazza R. Expression of transforming growth 
factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic 
role of a fibrogenic cytokine. J Clin Invest 96: 1137-1144, 1995. 
4. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima 
RS, and Khurana TS. Functional improvement of dystrophic muscle by myostatin 
blockade. Nature 420: 418-421, 2002. 
5. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, and Khurana TS. 
Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. 
Faseb J 19: 543-549, 2005. 
6. Brooks SV and Faulkner JA. Contractile properties of skeletal muscles 
from young, adult and aged mice. J Physiol 404: 71-82, 1988. 
7. Brooks SV and Faulkner JA. The magnitude of the initial injury induced by 
stretches of maximally activated muscle fibres of mice and rats increases in old 
age. J Physiol 497 ( Pt 2): 573-580, 1996. 
8. Brooks SV, Zerba E, and Faulkner JA. Injury to muscle fibres after single 
stretches of passive and maximally stimulated muscles in mice. J Physiol 488 ( 
Pt 2): 459-469, 1995. 
9. Byron CD, Hamrick MW, and Wingard CJ. Alterations of temporalis 
muscle contractile force and histological content from the myostatin and Mdx 
deficient mouse. Arch Oral Biol, 2005. 
10. Carlson CJ, Booth FW, and Gordon SE. Skeletal muscle myostatin mRNA 
expression is fiber-type specific and increases during hindlimb unloading. Am J 
Physiol 277: R601-606, 1999. 
11. Consolino CM and Brooks SV. Susceptibility to sarcomere injury induced 
by single stretches of maximally activated muscles of mdx mice. J Appl Physiol 
96: 633-638, 2004. 
12. Contri MB, Guerra D, Vignali N, Taparelli F, Marcuzzi A, Caroli A, and 
Ronchetti IP. Ultrastructural and immunocytochemical study on normal human 
palmar aponeuroses. Anat Rec 240: 314-321, 1994. 
13. Delforge G. Musculoskeletal Trauma : implications for sports injury 
management. Champaign, IL: Human Kinetics, 2002. 
14. Dellorusso C, Crawford RW, Chamberlain JS, and Brooks SV. Tibialis 
anterior muscles in mdx mice are highly susceptible to contraction-induced injury. 
J Muscle Res Cell Motil 22: 467-475, 2001. 
15. Donovan CM and Faulkner JA. Muscle grafts overloaded by ablation of 
synergistic muscles. J Appl Physiol 61: 288-292, 1986. 
66 
16. Ducomps C, Mauriege P, Darche B, Combes S, Lebas F, and Doutreloux 
JP. Effects of jump training on passive mechanical stress and stiffness in rabbit 
skeletal muscle: role of collagen. Acta Physiol Scand 178: 215-224, 2003. 
17. Engvall E and Wewer UM. The new frontier in muscular dystrophy 
research: booster genes. Faseb J 17: 1579-1584, 2003. 
18. Friden J and Lieber RL. Segmental muscle fiber lesions after repetitive 
eccentric contractions. Cell Tissue Res 293: 165-171, 1998. 
19. Gosselin LE, Adams C, Cotter TA, McCormick RJ, and Thomas DP. Effect 
of exercise training on passive stiffness in locomotor skeletal muscle: role of 
extracellular matrix. J Appl Physiol 85: 1011-1016, 1998. 
20. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, 
Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, and 
Georges M. A deletion in the bovine myostatin gene causes the double-muscled 
phenotype in cattle. Nat Genet 17: 71-74, 1997. 
21. Grobet L, Pirottin D, Farnir F, Poncelet D, Royo LJ, Brouwers B, 
Christians E, Desmecht D, Coignoul F, Kahn R, and Georges M. Modulating 
skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin 
gene. Genesis 35: 227-238, 2003. 
22. Hanyu T, Tajima T, Takagi T, Sasaki S, Fujimoto D, Isemura M, and 
Yosizawa Z. Biochemical studies on the collagen of the palmar aponeurosis 
affected with Dupuytren's disease. Tohoku J Exp Med 142: 437-443, 1984. 
23. Huijing P. Muscular force transmission: a unified, dual or multiple system? 
A review and some explorative experimental results. Arch Physiol Biochem 107: 
292-311, 1999. 
24. Kambadur R, Sharma M, Smith TP, and Bass JJ. Mutations in myostatin 
(GDF8) in double-muscled Belgian Blue and Piedmontese cattle. Genome Res 7: 
910-916, 1997. 
25. Kandarian SC and White TP. Mechanical deficit persists during long-term 
muscle hypertrophy. J Appl Physiol 69: 861-867, 1990. 
26. Khurana TS and Davies KE. Pharmacological strategies for muscular 
dystrophy. Nat Rev Drug Discov 2: 379-390, 2003. 
27. Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal 
muscle to mechanical loading. Physiol Rev 84: 649-698, 2004. 
28. Langley B, Thomas M, Bishop A, Sharma M, Gilmour S, and Kambadur R. 
Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. 
J Biol Chem 277: 49831-49840, 2002. 
29. Lee SJ and McPherron AC. Regulation of myostatin activity and muscle 
growth. Proc Natl Acad Sci U S A 98: 9306-9311, 2001. 
30. Lesch M, Parmley WW, Hamosh M, Kaufman S, and Sonnenblick EH. 
Effects of acute hypertrophy on the contractile properties of skeletal muscle. Am 
J Physiol 214: 685-690, 1968. 
31. Light N and Champion AE. Characterization of muscle epimysium, 
perimysium and endomysium collagens. Biochem J 219: 1017-1026, 1984. 
32. Livak KJ and Schmittgen TD. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
25: 402-408, 2001. 
67 
33. Macpherson PC, Dennis RG, and Faulkner JA. Sarcomere dynamics and 
contraction-induced injury to maximally activated single muscle fibres from 
soleus muscles of rats. J Physiol 500 ( Pt 2): 523-533, 1997. 
34. Macpherson PC, Schork MA, and Faulkner JA. Contraction-induced injury 
to single fiber segments from fast and slow muscles of rats by single stretches. 
Am J Physiol 271: C1438-1446, 1996. 
35. Mahoney DJ, Carey K, Fu MH, Snow R, Cameron-Smith D, Parise G, and 
Tarnopolsky MA. Real-time RT-PCR analysis of housekeeping genes in human 
skeletal muscle following acute exercise. Physiol Genomics 18: 226-231, 2004. 
36. Martyn JK, Bass JJ, and Oldham JM. Skeletal muscle development in 
normal and double-muscled cattle. Anat Rec A Discov Mol Cell Evol Biol 281: 
1363-1371, 2004. 
37. Matsakas A, Friedel A, Hertrampf T, and Diel P. Short-term endurance 
training results in a muscle-specific decrease of myostatin mRNA content in the 
rat. Acta Physiol Scand 183: 299-307, 2005. 
38. Maxwell LC, Faulkner JA, and Hyatt GJ. Estimation of number of fibers in 
guinea pig skeletal muscles. J Appl Physiol 37: 259-264, 1974. 
39. McCroskery S, Thomas M, Maxwell L, Sharma M, and Kambadur R. 
Myostatin negatively regulates satellite cell activation and self-renewal. J Cell 
Biol 162: 1135-1147, 2003. 
40. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, 
Sharma M, and Kambadur R. Improved muscle healing through enhanced 
regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 118: 3531-
3541, 2005. 
41. McMahon CD, Popovic L, Oldham JM, Jeanplong F, Smith HK, Kambadur 
R, Sharma M, Maxwell L, and Bass JJ. Myostatin-deficient mice lose more 
skeletal muscle mass than wild-type controls during hindlimb suspension. Am J 
Physiol Endocrinol Metab 285: E82-87, 2003. 
42. McPherron AC, Lawler AM, and Lee SJ. Regulation of skeletal muscle 
mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90, 1997. 
43. Mendler L, Zador E, Ver Heyen M, Dux L, and Wuytack F. Myostatin 
levels in regenerating rat muscles and in myogenic cell cultures. J Muscle Res 
Cell Motil 21: 551-563, 2000. 
44. Neuman RE and Logan MA. The determination of hydroxyproline. J Biol 
Chem 184: 299-306, 1950. 
45. Patel K and Amthor H. The function of Myostatin and strategies of 
Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal 
muscle. Neuromuscul Disord 15: 117-126, 2005. 
46. Philip B, Lu Z, and Gao Y. Regulation of GDF-8 signaling by the p38 
MAPK. Cell Signal 17: 365-375, 2005. 
47. Pirottin D, Grobet L, Adamantidis A, Farnir F, Herens C, Daa Schroder H, 
and Georges M. Transgenic engineering of male-specific muscular hypertrophy. 
Proc Natl Acad Sci U S A 102: 6413-6418, 2005. 
48. Prado LG, Makarenko I, Andresen C, Kruger M, Opitz CA, and Linke WA. 
Isoform diversity of giant proteins in relation to passive and active contractile 
properties of rabbit skeletal muscles. J Gen Physiol 126: 461-480, 2005. 
68 
49. Prentice WE. Rehabilitation techniques in sports medicine and athletic 
training. New York: McGraw-Hill, 2004. 
50. Rebbapragada A, Benchabane H, Wrana JL, Celeste AJ, and Attisano L. 
Myostatin signals through a transforming growth factor beta-like signaling 
pathway to block adipogenesis. Mol Cell Biol 23: 7230-7242, 2003. 
51. Rehfeldt C, Ott G, Gerrard DE, Varga L, Schlote W, Williams JL, Renne U, 
and Bunger L. Effects of the Compact mutant myostatin allele Mstn (Cmpt-
dl1Abc) introgressed into a high growth mouse line on skeletal muscle cellularity. 
J Muscle Res Cell Motil, 2005. 
52. Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, 
Fielder TJ, and Gonzalez-Cadavid NF. Lower skeletal muscle mass in male 
transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol 
Endocrinol Metab 285: E876-888, 2003. 
53. Roth SM and Walsh S. Myostatin: a therapeutic target for skeletal muscle 
wasting. Curr Opin Clin Nutr Metab Care 7: 259-263, 2004. 
54. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun 
T, Tobin JF, and Lee SJ. Myostatin mutation associated with gross muscle 
hypertrophy in a child. N Engl J Med 350: 2682-2688, 2004. 
55. Sharma M, Langley B, Bass J, and Kambadur R. Myostatin in muscle 
growth and repair. Exerc Sport Sci Rev 29: 155-158, 2001. 
56. Taylor WE, Bhasin S, Artaza J, Byhower F, Azam M, Willard DH, Jr., Kull 
FC, Jr., and Gonzalez-Cadavid N. Myostatin inhibits cell proliferation and protein 
synthesis in C2C12 muscle cells. Am J Physiol Endocrinol Metab 280: E221-228, 
2001. 
57. Thies RS, Chen T, Davies MV, Tomkinson KN, Pearson AA, Shakey QA, 
and Wolfman NM. GDF-8 propeptide binds to GDF-8 and antagonizes biological 
activity by inhibiting GDF-8 receptor binding. Growth Factors 18: 251-259, 2001. 
58. Thomas M, Langley B, Berry C, Sharma M, Kirk S, Bass J, and Kambadur 
R. Myostatin, a negative regulator of muscle growth, functions by inhibiting 
myoblast proliferation. J Biol Chem 275: 40235-40243, 2000. 
59. Tobin JF and Celeste AJ. Myostatin, a negative regulator of muscle mass: 
implications for muscle degenerative diseases. Curr Opin Pharmacol 5: 328-332, 
2005. 
60. Verrecchia F and Mauviel A. TGF-beta and TNF-alpha: antagonistic 
cytokines controlling type I collagen gene expression. Cell Signal 16: 873-880, 
2004. 
61. Wagner KR. Muscle regeneration through myostatin inhibition. Curr Opin 
Rheumatol 17: 720-724, 2005. 
62. Wagner KR, Liu X, Chang X, and Allen RE. Muscle regeneration in the 
prolonged absence of myostatin. Proc Natl Acad Sci U S A 102: 2519-2524, 
2005. 
63. Wagner KR, McPherron AC, Winik N, and Lee SJ. Loss of myostatin 
attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52: 832-836, 
2002. 
69 
64. Wanke T, Toifl K, Merkle M, Formanek D, Lahrmann H, and Zwick H. 
Inspiratory muscle training in patients with Duchenne muscular dystrophy. Chest 
105: 475-482, 1994. 
65. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill 
JJ, Jalenak M, Kelley P, Knight A, Maylor R, O'Hara D, Pearson A, Quazi A, 
Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka 
S, Zhao L, and Wolfman NM. Inhibition of myostatin in adult mice increases 
skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965-
971, 2003. 
66. Woessner JF, Jr. The determination of hydroxyproline in tissue and 
protein samples containing small proportions of this imino acid. Arch Biochem 
Biophys 93: 440-447, 1961. 
67. Wolfman NM, McPherron AC, Pappano WN, Davies MV, Song K, 
Tomkinson KN, Wright JF, Zhao L, Sebald SM, Greenspan DS, and Lee SJ. 
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. 
Proc Natl Acad Sci U S A 100: 15842-15846, 2003. 
68. Yang J, Ratovitski T, Brady JP, Solomon MB, Wells KD, and Wall RJ. 
Expression of myostatin pro domain results in muscular transgenic mice. Mol 
Reprod Dev 60: 351-361, 2001. 
69. Zhu X, Hadhazy M, Wehling M, Tidball JG, and McNally EM. Dominant 
negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS 
Lett 474: 71-75, 2000. 
70. Zhu X, Topouzis S, Liang LF, and Stotish RL. Myostatin signaling through 
Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative 
feedback mechanism. Cytokine 26: 262-272, 2004. 
71. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson 
KN, McPherron AC, Wolfman NM, and Lee SJ. Induction of cachexia in mice by 















Tendons play a significant role in the modulation of forces transmitted 
between bones and skeletal muscles and consequently protect muscle fibers 
from contraction-induced, or high strain, injuries.  Myostatin (GDF-8) is a 
negative regulator of muscle mass.  Inhibition of myostatin not only increases the 
mass and maximum isometric force of muscles, but also increases the 
susceptibility of muscle fibers to contraction-induced injury.  Furthermore, the 
expression of myostatin and the myostatin receptors, ACVR2B and ACVRB, 
were detectable in the tendons.  We hypothesized that myostatin would regulate 
the morphology and mechanical properties of tendons.  Surprisingly, compared 
with wild type (MSTN+/+) mice, the tendons of myostatin-null mice (MSTN-/-) were 
smaller, had a decrease in fibroblast density and a decrease in the expression of 
type I collagen.  Tendons of MSTN-/- mice also had a decrease in the expression 
of two genes that promote tendon fibroblast proliferation, scleraxis and 
tenomodulin.  Treatment of tendon fibroblasts with myostatin activated the p38 
MAPK and Smad2/3 signaling cascades, increased cell proliferation and 
increased the expression of type I collagen, scleraxis and tenomodulin.  
Compared with the tendons of MSTN+/+ mice, the mechanical properties of tibialis 
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anterior tendons from MSTN-/- mice had a greater peak stress, lower peak strain 
and a increased stiffness.  We conclude that in addition to the regulation of 
muscle mass and force, myostatin regulates the structure and function of tendon 
tissues. 
Introduction 
Tendons are a critical component of the musculoskeletal system.  
Situated, as tendons are, between bones and skeletal muscles, tendons are in a 
position to transmit forces generated within skeletal muscle fibers to bone and 
conversely transmit to skeletal muscle external loads placed on bone.  The 
extracellular matrix (ECM) of tendon tissue is composed primarily of type I 
collagen, as well as type III collagen, elastin and various proteoglycans and 
mucopolysaccharides.  Tendons are in series with both the contractile and non-
contractile elements of skeletal muscles as well as with bone.  Consequently, 
tendons are able to both store elastic energy during locomotion and protect 
muscle fibers from stretch-induced and contraction-induced injuries (15, 28).  
While considerable research has been conducted on the effects of exercise, 
immobilization and aging on the structure and function of tendons (19, 20), much 
less is known about the specific cytokines that regulate the structure and function 
of tendons. 
During embryonic development of the limb, early tendon development can 
be categorized into three phases, with each phase corresponding to an 
upregulation of the bHLH transcription factor scleraxis (13, 40).  Scleraxis is a 
marker of the tendon cell lineage (38, 40) and mice deficient in scleraxis display 
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severe tendon defects, have impaired locomotion and a complete inability to use 
their tails (34).  Scleraxis promotes the formation of tendon ECM by inducing the 
expression of type I collagen (23) and increases tendon fibroblast proliferation by 
the upregulation of the expression of the type II transmembrane protein, 
tenomodulin (41).  During the final stages of early tendon development, FGF-4 
and FGF-8, are secreted by adjacent myogenic cells and induce the expression 
of scleraxis  (5, 14). While FGF-4 and FGF-8 can induce scleraxis expression in 
the final phase of early tendon development, they do not appear to be 
responsible for the first and second phases of scleraxis expression (13).  In fact, 
another member of the GDF family may be a candidate for the regulation of 
scleraxis expression during the first and second phases of early tendon 
development (13), but the specific member of the GDF family has not been 
identified.   
Three members of the GDF family have been reported to influence the 
development of tendon tissue.  The placement of matrices coated with GDF-5, 
GDF-6 and GDF-7 into skeletal muscle induce the ectopic formation of tendon-
like tissue (50).  The tendons of GDF5-/- mice are smaller and display decreases 
in type I collagen content, peak stress, stiffness and energy absorption to yield 
(32).  The GDF5-/- mice also have severe bone and joint defects (32), but 
whether these changes in tendon mechanical properties arise due to a direct 
effect of GDF-5 on tendon cells or the associated skeletal defects is not clear.  
Compared with wild type mice, GDF7-/- mice have a minor tendon phenotype, 
with a decrease in proteoglycan content and smaller collagen fibrils, but no 
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differences in Achilles tendon mechanical properties, type I collagen content, or 
gross morphology (31).  Some evidence supports roles for GDF-5, GDF-6 and 
GDF-7 in tendon development, but whether other members of the GDF family 
influence tendon development has not been established.    
Myostatin (GDF-8) is a member of the TGF-ß superfamily of cytokines and 
is a negative regulator of skeletal muscle mass.  Myostatin binds to the activin 
type IIB (ACVR2B) and type IB (ACVRB) receptors and activates the Smad2/3, 
p38 MAPK and Erk1/2 signal transduction pathways (22, 37, 39, 51, 53).  
Myostatin regulates muscle mass by inhibiting the proliferation and differentiation 
of satellite cells (21, 26, 45), in addition to decreasing myofibrillar protein 
synthesis (49) and increasing the expression of the E3 ubiquitin ligase atrogin-
1/MAFbx (27).  Myostatin has a well established role in regulation of the structure 
and function of skeletal muscle, but the contribution of myostatin to the regulation 
of the structure and function of tendon has not been established. 
In addition to the regulation of muscle mass, myostatin has a profound 
impact on the contractile properties of skeletal muscles.  Inhibition of myostatin 
increases the maximum isometric force of skeletal muscles (3, 4, 30) and the 
susceptibility of muscles to contraction-induced injury (30).  During a lengthening 
contraction, the series elastic component (aponeurosis and tendon) of a muscle 
protects muscle fibers from damage by reducing the strain on fibers (15).  The 
MSTN-/- mice are much more susceptible to contraction-induced injury than the 
MSTN+/+ mice, an observation that is consistent with the possibility that myostatin 
might play a role in the regulation of the structural and functional properties of the 
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tendons. Our prior study (30) focused on the mechanical and contractile 
properties of the muscle and aponeurosis, but did not investigate the mechanical 
properties of the tendons of  MSTN-/- mice directly.  The overall aim of this 
investigation was to determine the role of myostatin in regulation of the 
mechanical and morphological properties of tendons.  We hypothesized that a 
deficiency in  myostatin results in smaller, stiffer, and more brittle tendons.    
Methods 
Animals.  All experiments were conducted in accordance with the 
guidelines of the University of Michigan Committee on the Use and Care of 
Animals.  Mice were housed in specific-pathogen-free conditions and were 
provided food and water ad libidum.  The line of MSTN-/- mice used in this study 
are of a C57Bl/6 background and were a kind gift of Dr. Se-Jin Lee.  The null 
MSTN allele was generated by replacing a portion of the third exon of the MSTN 
gene that encodes the C-terminal region of the mature myostatin protein with a 
neo cassette (29).   The wild type (MSTN+/+) littermates of the MSTN-/- mice 
served as controls.  The genotype of mice was determined by PCR-based 
analysis of DNA samples obtained via tail biopsy. 
Mechanical Testing of Tendons.  To evaluate the mechanical properties of 
the tibialis anterior tendon, the entire tendon unit (from the myotendinous junction 
to the base of the first metatarsal bone) was used.  The tibialis anterior tendon 
was chosen based on its relative uniformity of diameter, minimal aponeurosis 
and long gauge length (2).  Six month old male mice were anesthetized with 
intraperitoneal injection of Avertin (400 mg/kg).  Braded silk sutures were tied 
 75 
around the distal end of the tibialis anterior muscle just superior to the 
myotendinous junction and at the very distal end of the tendon, just superior to 
the first metatarsal. The length (Lo) of the tibialis anterior tendon was measured 
using digital calipers while the ankle was placed in maximal plantarflexion.  The 
tendon was removed by cutting the muscle just superior to the proximal suture 
and by removing the first metatarsal bone that was inferior to the distal suture.  
The tendon was immediately submerged in PBS maintained at 25º C.  The 
tendon was held at Lo and cross-sectional area (CSA) was calculated from 10 
evenly spaced width and depth measurements from high resolution digital 
photographs of both top and side views of the tendon.  Side views were obtained 
using a 90º prism embedded in the side of the bath.  These measurements were 
fitted to an ellipse and the ellipse area was used as the tendon CSA. 
The proximal end of the tendon was attached to a dual-mode servo 
motor/force transducer (model 305C, Aurora Scientific) and the distal end was 
attached to a fixed post.  Custom designed software (LabVIEW 7.1, National 
Instruments) controlled the servo motor motion and recorded force and strain 
data at a sampling rate of 20 kHz.  The tendon was stretched to a 100% strain 
relative to Lo at a velocity of 1 Lo × s-1.  Peak stress was defined as the stress 
that further increases in length resulted in a rupture of the tendon or the point at 
which yield strength had been reached without a frank rupture of the tendon.  
Peak strain was defined as the strain at which peak stress was reached. The 
data were fitted by either a fourth or fifth order polynomial function with an R2 ≥ 
0.9995.  Peak tendon stiffness was calculated by differentiating the fitted 
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polynomial and then determining its maximum value between Lo and peak strain.  
Average tendon stiffness was calculated as the mean value of the differentiated 
polynomial between Lo and peak strain.  The energy absorption to the yield point 
was calculated by integrating the force-displacement function from Lo through 
peak strain and normalizing this value by the mass of the tendon. 
Histology.  To determine the density of fibroblasts in tendon tissue, tibialis 
anterior tendons were removed from 6 month old anesthetized mice, placed in 
embedding media and snap frozen in using isopentane cooled with dry ice.  
Sections were obtained from the proximal, middle and distal thirds of the tendon 
and stained with hematoxylin and eosin.  Fibroblast density for the entire tendon 
was calculated by taking the mean value of the counts from each of the three 
regions of the tendon.   
Tendon Fibroblast Isolation, Culture And Treatment With Myostatin.  
Hindlimb and forelimb tendons were isolated from anesthetized 4 month old male 
MSTN+/+ mice, carefully trimmed of muscle and fat tissue, finely minced and 
placed in DMEM + 0.05% Type II Collagenase (Invitrogen) in a shaking water 
bath for 2 h at 37º C.  Following dissociation, fibroblasts were pelleted by 
centrifugation, resuspended in DMEM + 2% fetal bovine serum (FBS) + 1% 
antibiotic-antimycotic (AbAm) and expanded in 100 mm culture dishes coated 
with type I collagen (BD Biosciences).  Fibroblasts were passaged twice upon 
reaching 70% confluence.  Following the last passage, 2 × 104 fibroblasts were 
plated in 35 mm culture dishes coated with type I collagen and expanded until 
reaching 80% confluence.  Fibroblasts were then starved of serum for 24 hours 
 77 
prior to treatment by replacing serum containing media with DMEM + 1% AbAm 
+ 1× Insulin-Transferrin-Selenium supplement (ITS, Invitrogen).  Recombinant 
murine myostatin, produced in NS0 mouse myeloma cells (R & D Systems), was 
dissolved into the serum-free media at a final concentration of 500 or 1000 
ng/mL.  Stock solutions of the p38 MAPK inhibitor SB-203580 (10) and the 
Smad2/3 inhibitor SB-431542 (17) were prepared by dissolving these solid 
anhydrous compounds in DMSO at a concentration of 10mM.  These stock 
solutions were then added to serum-free media containing 1% DMSO at a final 
concentration of 10µM for SB-203580 and 5µM for SB-431542.  Fibroblasts were 
pretreated with SB-203580 or SB-431542 for 1 hour prior to treatment with 
myostatin.   
Cell Proliferation and Immunocytochemistry.  Following serum starvation, 
fibroblasts were incubated in serum free media containing 20µM of the thymidine 
analog 5-bromo-2′-deoxyuridine (BrdU, Sigma) for 3 hours.  Fibroblasts were 
rinsed twice with serum free media and treated with myostatin, SB-203580 and 
SB-431542 as described above.  Following 24 hours of treatment, fibroblasts 
were rinsed with PBS, fixed in ice cold methanol and permeabilized with 0.5% 
Triton X-100.  The BrdU epitope was exposed by digesting DNA with 200U/mL of 
EcoRI and denaturing DNA with 2N HCl.  BrdU was visualized using an anti-
BrdU antibody (G3G4, SJ Kaufman, Developmental Studies Hybridoma Bank) 
and a Cy3-conjugated secondary antibody (Jackson ImmunoResearch).  DAPI 
(Sigma) was used as a non-specific nuclear stain.  Twenty five random fields 
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were counted per dish.  Cell proliferation data presented are the mean ± SE 
values of three independent experiments.   
RT-PCR.  RNA was isolated from samples using an RNeasy Mini Kit 
(Qiagen).  When isolating RNA from whole tendons, the tissue was treated with 
type II collagenase and proteinase K prior to vigorous homogenization in 
guanidine thiocyanate buffer.  Due to the smaller size of the tibialis anterior 
tendons, we were unable to consistently obtain adequate quantities of RNA 
with an A260/A280 ratio between 1.8 and 2.0.  We instead used RNA from Achilles 
tendons, as we were able to obtain RNA with A260/A280 ratios between 1.8 and 
2.0 from these tendons.  RNA was treated with DNase I and reverse 
transcribed using an Omniscript RT kit (Qiagen) and oligo(dT)15 primers.  
Primers for PCR reactions (Table 3.1) were designed to generate amplicons that 
span multiple exons.  For standard PCR, 250ng of cDNA underwent 42 rounds of 
amplification using GoTaq Green (Promega).  PCR products were separated 
using a 2% agarose gel.  For real-time PCR, cDNA was amplified using a 
QuantiTect SYBR Green I PCR system (Qiagen) with Uracil-N-Glycosylase 
(Invitrogen) in an Opticon 2 real-time thermal cycler (Bio-Rad).  qPCR reactions 
were conducted in quadruplicate for each sample.  We used the methods of 
Livak and Schmittgen (25) to determine optimal loading quantities of cDNA and 
in the validation of GAPDH as a housekeeping gene.  Gene expression was 
normalized to GAPDH expression using the 2-ΔΔC(t) method (25). The presence of 
single amplicons from qPCR reactions was verified by melting curve analysis as 
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well as electrophoresis using a 2% agarose gel.  qPCR data presented is the 
combined means ± SE of three independent experiments. 
Immunoblot.  Tendon fibroblasts, prepared as described above and 
starved of serum for 24 hours, were treated for two hours with myostatin, SB-
203580 and SB-431542 for 2 hours.  Following treatment, cells were rinsed with 
PBS and scraped and homogenized in Laemmli's sample buffer with 1:20 ß-
mercaptoethanol, 1:20 protease inhibitor cocktail (Sigma) and 1:40 phosphatase 
inhibitor cocktail (Sigma), and then placed in boiling water for 5 minutes. Protein 
concentration of the samples was determined using an RC DC Protein Assay 
(Bio-Rad).  Equal amounts of protein were loaded into polyacrylamide gels and 
subjected to electrophoresis using a 4% stacking, 10% resolving gel.  Proteins 
were transferred to a 0.45 µm nitrocellulose membrane, stained with Ponceau S 
to verify equal protein transfer and blocked using casein (Vector Labs).  
Antibodies against p38 MAPK and phospho-p38 MAPK were purchased from 
Cell Signaling.  Primary antibodies against Smad2/3 and phospho-Smad2/3 were 
purchased from Millipore.  Biotinylated secondary antibodies were purchased 
from Pierce Biotechnology.  Avidin-HRPO conjugates were purchased from 
Vector Labs.  Membranes were developed using SuperSignal West Dura 
enhanced chemiluminescent reagents (Pierce Biotechnology) and visualized 
using a FluorChem chemiluminescent documentation system (Alpha Innotech). 
Statistical Analysis.  Results are presented as means ± SE.  KaleidaGraph 4.02 
software was used to conduct statistical tests.  For gene expression and cell 
proliferation data from cell culture experiments, differences between groups were 
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tested with a one-way ANOVA with α = 0.05.  Fisher’s least significant post hoc 
test was used to identify specific differences when significance was tested.  For 
all other data, differences between MSTN+/+ and MSTN-/- mice was tested with 
Student’s t-test with α = 0.05.  
Results 
MSTN-/- mice have greater muscle masses but smaller tendons.  We first 
determined the impact of myostatin deficiency on the mass of tendons.  Although 
the mass of the tibialis anterior (TA) muscles of MSTN-/- mice were 72% greater 
than MSTN+/+ mice, the TA tendons of the MSTN-/- mice were 40% smaller 
(Table 3.2).  When the tendon mass was normalized by the muscle mass, the 
MSTN-/- mice had a 64% decrease in the tendon/muscle mass ratio.  Similar 
results were observed for soleus muscles and Achilles tendons.  The mass of the 
soleus muscles of MSTN-/- mice were 82% greater than MSTN+/+ mice, but the 
Achilles tendons of the soleus muscles of MSTN-/- mice were 44% smaller than 
those of MSTN+/+ mice.  Consequently, for MSTN-/- mice the Achilles 
tendon/soleus muscle mass ratio was decreased by 69%.   Furthermore, for the 
MSTN-/- mice, the CSA of the TA tendons were 50% smaller than those of the 
MSTN+/+ mice (Table 3.3).  The lengths and densities of the TA tendons of 
MSTN-/- and MSTN+/+mice were not different.  CSA and the lengths and densities 
of Achilles tendons were not determined, as the Achilles tendons were not used 
in testing of mechanical properties. 
Tendon fibroblasts express the myostatin receptors and activate the p38 
MAPK and Smad2/3 signaling pathways in response to myostatin treatment.  
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Subsequently, the expression of the myostatin receptors, ACVR2B and ACVRB, 
was examined in tendon fibroblasts.  Transcripts for both ACVR2B and ACVRB 
were identified in whole tendon tissue, as well as in cultured tendon fibroblasts 
(Figure 3.1A).  The myostatin transcript was also detected in tendon tissue and in 
cultured fibroblasts.  Due to the close anatomical proximity between muscle and 
tendon tissue, the purity of tendon samples was verified by probing for the 
presence of type IIa myosin heavy chain and MyoD.  Neither muscle specific 
gene was detected in tendon samples. 
The next step was to determine whether cultured tendon fibroblasts 
activate intracellular signaling cascades in response to myostatin treatment.  
Myostatin induced the phosphorylation of both p38 MAPK and Smad2/3 (Figure 
3.1B).  When cells were treated with myostatin in the presence of the p38 MAPK 
inhibitor SB-203580 (10), the phosphorylation of p38 MAPK did not occur.  
Consequently, SB-203580 was specific to the p38 MAPK pathway, as this 
inhibitor did not block the phosphorylation of Smad2/3.  For cells that were 
treated with myostatin in the presence of the Smad2/3 inhibitor SB-431542 (17), 
the phosphorylation of Smad2/3 was blocked with no effect on the 
phosphorylation of p38 MAPK.  These results indicated that tendon fibroblasts 
expressed the myostatin receptors, were responsive to myostatin treatment and 
this response could be blocked by the use of SB-203580 and SB-431542. 
Myostatin induces the proliferation of tendon fibroblasts.  To determine 
whether myostatin induced the proliferation of tendon fibroblasts, fibroblasts were 
pulsed with BrdU and the cells were subsequently treated with myostatin, SB-
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203580 and SB-431542 for 24h.  Treatment with 1000 ng/mL of myostatin 
increased tendon cell proliferation by 37% over controls (Figure 3.2A).  While the 
inhibition of the p38 MAPK pathway was sufficient to decrease the myostatin-
mediated increase in fibroblast proliferation, the inhibition of the Smad2/3 
pathway did not block the myostatin-mediated increase in fibroblast proliferation.  
Compared with MSTN+/+ mice, the density of fibroblasts in whole tendon tissue 
was 47% less than for the MSTN-/- mice (Figure 3.2B).  These results indicated 
that myostatin was a potent regulator of tendon cell proliferation. 
Myostatin induces the expression of scleraxis, tenomodulin and type I 
collagen in tendon fibroblasts.  The next step was to determine if myostatin 
regulated the expression of scleraxis and tenomodulin, the two genes that induce 
the proliferation of tendon fibroblasts.  Treatment with 1000 ng/mL of myostatin 
resulted in a greater than two-fold increase in scleraxis expression (Figure 3.3A).  
Inhibiting the p38 MAPK pathway resulted in a 70% decrease in scleraxis 
expression, while the inhibition of the Smad2/3 pathway resulted in a 50% 
increase in scleraxis expression.  Myostatin treatment doubled the expression of 
tenomodulin, and inhibition of both the p38 MAPK and Smad2/3 pathways to 
blocked the myostatin-mediated increase in tenomodulin expression (Figure 
3.3B).  Compared with MSTN+/+ mice, MSTN-/- mice had a 64% decrease in 
scleraxis expression (Figure 3.3D) and a 63% decrease in tenomodulin 
expression (Figure 3.3E).  These results indicated that the mechanisms 
responsible for the myostatin-mediated increase in fibroblast proliferation were 
due to an upregulation of scleraxis and tenomodulin. 
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Due to the smaller mass and CSA of the tendons of MSTN-/- mice, the 
impact of myostatin on the major structural protein of tendon, type I collagen, was 
determined.  Treatment with 1000 ng/mL of myostatin resulted in a 67% increase 
in the expression of type I collagen (Figure 3.3C).  The inhibition of either the p38 
MAPK, or the Smad2/3 pathway was sufficient to block this increase in type I 
collagen expression.  Compared with MSTN+/+ mice, a 54% decrease in type I 
collagen expression was observed in the tendons of MSTN-/- mice (Figure 3.3F).  
Taken together, the cell proliferation and gene expression data indicated that the 
smaller tendons of the MSTN-/- mice depended on a decrease in tendon 
fibroblast proliferation and on the production of the constituents of the ECM. 
MSTN-/- mice have stiff, brittle tendons.  The profound impact of myostatin 
on the structure of tendons indicated that myostatin-deficiency likely influenced 
the mechanical properties of tendons.  Consequently, the stress-strain 
relationships of tendons from MSTN+/+ and MSTN-/- mice were measured (Figure 
3.4A).  Compared with the tendons of MSTN+/+ mice, those of MSTN-/- mice 
reached a greater than two-fold higher peak stress before yielding, but reached 
less than half of the peak strain before yielding (Table 3.3).  Tendons of MSTN-/- 
mice also demonstrated a fourteen-fold greater peak stiffness and average 
stiffness values than those of MSTN+/+ mice (Figure 3.4B and Table 3.3).  
Despite the different stress-strain and stiffness properties of tendons from 
MSTN+/+ and MSTN-/- mice, the tendons absorbed the same amount of energy 
before reaching the yield point (Figure 3.4C and Table 3.3).   These results 
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indicated that the loss of myostatin had a major impact on the mechanical 
properties of tendons. 
Discussion 
Myostatin has a well characterized role in the regulation of the structure 
and function of skeletal muscles.  Although the myostatin transcript has been 
detected previously in tendons (16), our results provide the first evidence that 
myostatin  regulates directly the structure and function of tendons.  For the 
MSTN-/- mice, the deficiency in myostatin resulted in small, brittle, hypocellular 
tendons.  The difference in tendon phenotypes between the MSTN-/- and 
MSTN+/+ mice is clearly not attributable to any indirect influence of a greater 
muscle mass of the MSTN-/- mice, as both genotypes were limited to cage 
sedentary activity levels and the two genotypes showed no differences in body 
masses.  Consequently, the tendons of both groups of mice experienced very 
similar mechanical loads throughout their lifespan and the dramatic change in the 
structure and function of tendons could be attributed directly to the effect of 
myostatin on tendon fibroblasts.  In addition, this conclusion is supported further 
by the concurrent cell culture experiments.  
While myostatin promotes the synthesis of intramuscular collagen content 
and skeletal muscle fibroblast proliferation (30, 52), whether myostatin regulated 
the collagen content and proliferation of fibroblasts of tendon was not 
immediately evident.  The inhibition of myostatin in mdx mice, a murine model of 
Duchenne muscular dystrophy, decreased fibrosis and increased maximum 
isometric force production (3, 4, 48).  Compared with MSTN+/+ mice, a decrease 
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in the type I collagen content of EDL muscles of MSTN-/- mice was observed 
(30).  Myostatin also induced the expression of type I collagen in skeletal muscle 
myotubes (30) and muscle-derived fibroblasts (52) and increased the 
proliferation of cultured muscle-derived and NIH/3T3 fibroblasts (52).  The 
current investigation indicated that myostatin also promotes fibroblast 
proliferation and type I collagen synthesis in tendons, both in vivo and in vitro.  
A rapidly growing body of literature supports the role of scleraxis and 
tenomodulin in the embryonic development of tendons (5, 12-14, 23, 34, 38, 40, 
41), but little is known regarding their function in adult tendons.  FGF-4 and FGF-
8 directly induced the expression of scleraxis in tendon fibroblasts (5, 6, 14, 43).  
Furthermore, TGF-ß induced the expression of scleraxis in osteosarcoma cells 
(24) .  Overexpression of scleraxis in tendon fibroblasts either directly or 
indirectly resulted in the upregulation of tenomodulin (41). The relative 
expression of scleraxis and tenomodulin in the tendons of MSTN+/+ and MSTN-/- 
mice in this study were in good agreement with the data on tendon mass and cell 
density. Similar to tenomodulin deficient mice, the tendons of MSTN-/- mice were 
hypocellular (12).  The results from the current study indicate that scleraxis and 
tenomodulin are expressed in adult tendons and that both genes are downstream 
targets of myostatin, that activates similar signal transduction cascades as TGF-
ß and FGF.  
During several stages of embryonic development, myogenic cells and 
tendon precursor cells interact with each other to ensure proper spatial alignment 
and proper timing of differentiation events (13, 18).  While myostatin was 
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expressed in myogenic cells and decreased the expression of the myogenic 
genes MyoD, Myf-5 and Pax3 in these cells, myostatin was also expressed in 
non-myogenic cells of the ectoderm (1) but the reason for the expression of 
myostatin in non-muscle cells was not known.  Scleraxis expression occurred in 
three phases of tendon development (13, 40), with the final phase initiated by 
FGF-4 and FGF-8 (5, 14) produced in adjacent myogenic cells.  The signal that 
initiated the first phase of scleraxis expression in tendon progenitor cells is not 
known, but this signal does not come from muscle cells, as removal of myogenic 
cells does not alter scleraxis expression (14).  The ectoderm appeared critical to 
the induction of the first stage of scleraxis expression, as ablation of the 
ectoderm abolished the first phase of scleraxis expression (40).  Myostatin was 
expressed in the ectoderm around the time of the first phase of scleraxis 
expression (1) and removal of the ectoderm resulted in a downregulation of 
scleraxis.  Consequently, myostatin may play a direct role in the development of 
tendons by regulating the initial expression of scleraxis.  
One of the most striking differences between the mechanical properties of 
MSTN+/+ and MSTN-/- mice was the fourteen-fold increase in the stiffness of 
tendons in MSTN-/- mice.  The stiffness of tendons is a critical factor in 
determining the damage to muscle fibers during lengthening contractions.  
Immediately following a two-stretch lengthening contraction protocol, the EDL 
muscles of MSTN-/- mice had a 15% greater force deficit than MSTN+/+ mice (30).  
The force deficit following a contraction-induced injury is directly related to the 
strain on the muscle fibers during the lengthening contraction (7). Consequently, 
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the series elastic component of a muscle protects the sarcomeres from damage 
by limiting the strain of the muscle fibers during the contraction (15). Similarly, 
the increased stiffness of tendons increases the strain on the muscle fibers plays 
a direct role in the greater force deficit observed for the muscles of MSTN-/- mice 
compared with MSTN+/+ mice following a lengthening contraction protocol (30).  
While the mechanisms responsible for the increased stiffness of tendons from 
MSTN-/- mice are not known, the stiffening of tendons is thought to arise as a 
result of the increased crosslinking between type I collagen molecules (47).  
Future studies that evaluate the biochemical and molecular differences between 
the tendons of MSTN+/+ and MSTN-/- mice are necessary to determine the 
mechanisms behind the regulation of tendon mechanical properties by myostatin.  
Considerable interest has focused on the potential use of myostatin 
inhibitors in the treatment of muscle wasting diseases such as Duchenne 
muscular dystrophy (8, 35, 46).  Muscles of mdx mice (9, 11, 33, 36, 44) and 
patients with Duchenne muscular dystrophy (42) are highly susceptible to 
contraction-induced injury.  A profound increase in the stiffness of tendons would 
likely further increase the susceptibility of dystrophic muscles to contraction-
induced injury and exacerbate the symptoms of muscular dystrophy.  A careful 
evaluation of the long term impact of myostatin suppression on the mechanical 
properties of tendons of dystrophic muscles, and the susceptibility of dystrophic 
muscles to contraction-induced injury, is warranted.  
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Figure 3.1.  Tendon fibroblasts expressed the myostatin receptors and activated 
signal transduction cascades in the presence of myostatin.  (A) PCR analysis of 
cDNA libraries from whole tendon tissue and cultured tendon fibroblasts 
indicated that tendon fibroblasts expressed both of the myostatin receptors 
(ACVRB and ACVR2B) as well as myostatin (MSTN) itself.  MHC2A and MyoD 
were used as negative controls to indicate purity of tendon samples.  (B) 
Treatment of tendon fibroblasts with myostatin for 2h results in the 
phosphorylation of both p38 MAPK and Smad2/3.  The p38 MAPK inhibitor SB-
203580 was able to specifically block the myostatin-mediated phosphorylation of 
p38 MAPK, and the Smad2/3 inhibitor SB-431542 was able to specifically block 
the myostatin-mediated phosphorylation of Smad2/3. +, 500ng/mL of myostatin. 




Figure 3.2.  Myostatin induced the proliferation of tendon fibroblasts.  (A) 
Treatment of tendon fibroblasts for 24h with myostatin increases cell proliferation 
as measured by the relative incorporation of the thymidine analog BrdU.  N = 3 
independent experiments.  +, 500ng/mL of myostatin. ++, 1000ng/mL of 
myostatin.  *, significantly different from control group at P < 0.05.  (B) Cell 
density data from tibialis anterior tendon sections stained with H&E.  MSTN-/- 
mice a lower fibroblast density than MSTN+/+ mice.  N = 6 tendons per genotype.  
*, significantly different from MSTN+/+ at P < 0.05. 
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Figure 3.3.  Myostatin induces the expression of scleraxis, tenomodulin and 
collagen Iα2 genes in tendon fibroblasts.  Treatment of cells with myostatin for 
24h increases the relative expression of scleraxis (A), tenomodulin (B) and 
collagen Iα2 (C) normalized to GAPDH. +, 500ng/mL of myostatin. ++, 
1000ng/mL of myostatin.  *, significantly different from control group at P < 0.05. 
There is a decrease in the expression of scleraxis (D), tenomodulin (E) and 
collagen Iα2 (F) normalized to GAPDH in tendons of MSTN-/- mice.  N = 4 
tendons per genotype.  *, significantly different from MSTN+/+ at P < 0.05. 
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Figure 3.4.  Mechanical properties of tibialis anterior tendons of MSTN+/+ and 
MSTN-/- mice.  (A) The stress-strain relationship of tendons from MSTN+/+ and 
MSTN-/- mice indicate that MSTN-/- mice develop a higher peak stress but have a 
lower peak strain.  (B) MSTN-/- mice have a greater peak stiffness and average 
stiffness than MSTN+/+ mice.  (C) The energy absorbed to the yield point is not 
different between MSTN+/+ and MSTN-/- mice. N = 5 tendons per genotype.  *, 
significantly different from MSTN+/+ at P < 0.05. 
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Gene Forward Primer (5' - 3') Reverse Primer (5' - 3') 
ACVRB GCTGGAAAGCCCTTCTACTG TGATGACCAGGAAGACGATG 
ACVR2B GAAGATGAGGCCCACGATTA GGAGGTCACCAGAGAGACGA 
COL1A2 CCAGCGAAGAACTCATACAGC GGACACCCCTTCTACGTTGT 
GAPDH TGGAAAGCTGTGGCGTGAT TGCTTCACCACCTTCTTGAT 
MHC2A CCAAGTCAGAGGCAAAGAGG TCTTTGATTTTGGCCTCCAG 
MSTN TGCAAAATTGGCTCAAACAG GCAGTCAAGCCCAAAGTCTC 
MYOD CGCTCCAACTGCTCTGATG TAGTAGGCGGTGTCGTAGCC 
TNMD TGTACTGGATCAATCCCACTCT GCTCATTCTGGTCAATCCCCT 
 
Table 3.1.  PCR primer sequences.  Primers for RT-PCR and RT-qPCR.  
Primers are designed to generate an amplicon which spans two or more exons 




 MSTN+/+ MSTN-/- 
Mouse Mass (g) 33.8±1.1 36.8±1.1 
TA Tendon Mass (mg) 1.30±0.10 0.78±0.05* 
TA Muscle Mass (mg) 51.84±1.58 89.34±3.92* 
TA Tendon/Muscle Mass Ratio 0.025±0.002 0.009±0.001* 
Achilles Tendon Mass (mg) 2.34±0.10 1.32±0.10* 
Soleus Mass (mg) 8.10±0.29 14.80±0.21* 
Achilles Tendon/Soleus Muscle Mass Ratio 0.291±0.005 0.090±0.008* 
 
Table 3.2.  Whole animal, muscle and tendon masses.  Values are means ± SE.  




 MSTN+/+ MSTN-/- 
Lo (mm) 6.78±0.28 6.12±0.10 
CSA (mm2) 0.16±0.03 0.08±0.01* 
Density (mg/mm3) 1.54±0.42 1.63±0.06 
Peak Strain (ΔL/Lo) 0.75±0.02 0.33±0.04* 
Peak Stress (kPa) 8250±1223 20300±1067* 
Peak Stiffness (mN/mm2) 95.0±17.1 1386±212* 
Average Stiffness (mN/mm2) 49.6±8.3 711±253* 
Energy Absorption (mJ/mg) 1.93±0.56 1.89±0.27 
 
Table 3.3.  Morphological and mechanical properties of tibialis anterior tendons.  
Values are means ± SE.  N = 5 for each genotype. *Significantly different from 
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Summary and Conclusion 
 
Overview 
 Prior to the studies described in this dissertation, myostatin was known to 
be a negative regulator of muscle mass.  What was not clear was whether or not 
the deficiency of myostatin had an impact on the function of either skeletal 
muscles or the structure of function of tendons.  To clarify the role of myostatin 
deficiency on the function of skeletal muscles the structure and function of 
tendons, a combined approach was utilized that involved the use of transgenic 
animals for structural and functional studies and of cell culture work to establish 
the molecular mechanisms responsible for the structural and functional changes.  
The studies described in the previous three chapters indicate that myostatin 
regulates the structure and function of both skeletal muscles and tendons. 
Discussion of Findings and Future Directions - Skeletal Muscle 
 Prior to the preliminary studies described in Chapter I and the study 
described in Chapter II, the deficiency of myostatin was known to increase the 
mass of skeletal muscles (10, 17).  Furthermore, although myostatin deficiency 
improved the function of dystrophic muscles (1), the role of myostatin in the 
regulation of the function of healthy, non-dystrophic muscle tissue had not been 
determined.  Consequently, the findings from the first and second chapters can 
be divided into two separate categories – structure and function. 
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 Structure.  The genetic deficiency of myostatin leads to both hypertrophy 
and hyperplasia of fast-fibered muscles (17).  In prior studies, the measurements 
of the number of fibers in the skeletal muscles were determined from cross 
sections of muscles that might not provide an accurate indication of the true 
number of fibers (15).  By digesting the ECM of EDL and soleus muscles and 
counting all of the fibers present in the muscle, we have now demonstrated that 
the deficiency of myostatin leads to a bona fide hyperplasia.   
 In addition to a greater number of fibers, myostatin deficiency leads to an 
increase in the CSAs of fibers.  While myostatin inhibition increases satellite cell 
proliferation (12, 16, 27), this satellite cell inhibition does not appear to be wholly 
sufficient to explain the hypertrophic response that occurs with the inhibition of 
myostatin.  Administering mice an inhibitory antibody against myostatin resulted 
in a 14% increase in muscle mass in only two weeks (29).  This increase in 
muscle mass is unlikely to occur simply by modulating satellite cell activity.  The 
preliminary study presented in Chapter I demonstrated that the deficiency of 
myostatin leads to a marked decrease in ubiquitinated myosin heavy chain and a 
decrease in atrogin-1 expression.  No difference in relative myofibrillar protein 
content was observed between the muscles of MSTN+/+ and MSTN-/- mice.  
These results suggest that the inhibition of myostatin leads to muscle fiber 
hypertrophy by the inhibition of protein degradation.   
 The deficiency of myostatin reduced collagenous fibrosis in mdx mice (1, 
2, 28), but whether myostatin regulate the expression of type I collagen directly 
was not clear.  The cell culture studies from Chapter II demonstrated that 
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myostatin increased directly the expression of type I collagen.  Additionally, 
myostatin-deficient EDL muscles showed a decrease in whole muscle collagen 
content.  These results indicated that, in addition to regulating the numbers of 
fibers in a muscle, myostatin regulated the ECM of skeletal muscle.   
 Function.  In addition to the profound impact on the structure of skeletal 
muscle, myostatin had an impact on the function of skeletal muscle through the 
hypertrophy and hyperplasia present in the skeletal muscles of myostatin-
deficient mice, and the impact these changes had on the contractile properties of 
muscles.  The studies from Chapter II demonstrated that the deficiency of 
myostatin increased the Po of both EDL and soleus muscles.  When Po was 
normalized to the CSA of the muscles to calculate sPo, an unexpected finding 
was observed.  As a muscle undergoes hypertrophy and is able to generate a 
greater Po, the sPo will usually decrease due to the increase in θ (15).  Despite 
having a greater number of fibers, fiber CSA, Po and θ,  the EDL muscles from 
MSTN+/- and soleus muscles from MSTN-/- mice did not show a decrease in sPo.  
In contrast, the EDL muscles of the MSTN-/- mice, that had a greater number of 
fibers, fiber CSA, Po and θ did suffer from a decrease in sPo.  For a muscle that 
undergoes hypertrophy, a threshold appears to exist above which a decrease in 
sPo occurs.  In contrast, for small increases in muscle CSA, mass and Po, sPo 
does not change. 
 Furthermore, the deficiency of myostatin was found to increase the 
susceptibility of muscles to contraction-induced injury.  Following contraction-
induced injury, the EDL muscles of MSTN-/- mice had greater relative force 
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deficits than those of MSTN+/+ mice.  Despite having a greater force deficit 
following injury, the work done to stretch the muscles of MSTN-/- mice was less 
than MSTN+/+ and MSTN+/- mice.  As the series elastic component of muscles 
can protect fibers from injury (9), we initially hypothesized that the series elastic 
component of muscles of the MSTN-/- mice were more compliant, exceeded their 
elastic limit during the lengthening contractions, and therefore no longer acted as 
mechanical springs.  This lead to a subsequent study of tendon structure and 
function, presented in Chapter III.  After completion of the investigation of the 
properties of tendon structure and function, the initial hypothesis as to why the 
EDL muscles of MSTN-/- mice are more susceptible to contraction-induced injury 
was rejected.  The rejection was based on the observation that the tendons of 
MSTN-/- mice were fourteen times stiffer than the tendons of MSTN+/+ mice and 
the peak stiffness occurred at an early strain value.  These findings suggested 
that the series elastic component of the tendons of the MSTN-/- mice were so stiff 
that they acted as a rigid body and did not take up much, if any, strain as the 
muscle was stretched.  Extremely stiff tendons appear to be the reason why the 
deficiency of myostatin increases the susceptibility of the fast-fibered EDL 
muscles to contraction-induced injury.   
 Future Studies.  An interesting finding from the studies presented in 
Chapter II is that the EDL muscles of MSTN+/- mice developed a greater Po than 
the MSTN+/+ mice, but unlike the MSTN-/- mice, no difference was observed in 
sPo, or force deficit, after the injury.  Even though the collagen content of the EDL 
muscles of MSTN+/- mice was less than that of MSTN+/+ mice, this did not 
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increase the susceptibility of these muscles to contraction-induced injury.  As the 
MSTN+/- mice have a 20% decrease in circulating myostatin levels compared to 
MSTN+/+ mice, this suggests that the partial suppression of myostatin is able to 
increase force production of muscles without making the muscles more 
susceptible to injury.  Based on the preliminary data in Chapter I that showed that 
myostatin increased protein degradation and the data in Chapter II that showed 
that myostatin increased type I collagen expression, the use of a pharmaceutical 
inhbitor of myostatin might be beneficial in the treatment of severe contraction-
induced injuries.  Following the induction of a severe lengthening contraction 
injury to the muscles of a mouse, the administration of a pharmaceutical inhibitor 
such as a monoclonal antibody against myostatin, the propeptide of myostatin, or 
a small peptide that blocks the interaction of myostatin with its receptors, the 
effect of myostatin inhibition on the recovery from a severe contraction induced 
injury could be determined.  Based on the findings from Chapters I and II, the  
hypothesis that inhibition of myostatin promotes the long-term recovery of muscle 
from severe injury by blocking protein degradation and reducing fibrosis appears 
promising.     
Discussion of Findings and Future Directions - Tendon 
The study described in Chapter III demonstrated, for the first time, that 
myostatin has a profound impact on the structure and function of tendon tissue.  
The study not only described and characterized the phenotype of tendons from 
myostatin-deficient mice, but also demonstrated that myostatin can directly 
activate intracellular signal transduction cascades in tendon fibroblasts and 
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explored the possible cellular and molecular mechanisms behind the tendon 
phenotype.  In addition to showing that myostatin can directly regulate tendon 
structure and function, Chapter III demonstrated for the first time that the bHLH 
transcription factor scleraxis continues to be expressed in adult tendon 
fibroblasts and that myostatin increases the expression of scleraxis directly.  
Tenomodulin was also shown to be a downstream target of myostatin signaling.  
While tenomodulin deficient mice displayed hypocellular tendons with no change 
in ECM structure or size (3), the mechanisms behind the control of cell 
proliferation by tenomodulin are not known.  Three future studies are suggested 
that would provide further insight into the regulation of tendon physiology. 
Study 1 – Myostatin-mediated regulation of scleraxis expression during 
development.  During the development of tendon structures in the limb, tendon 
development can be categorized into three phases, each phase corresponding to 
an upregulation of scleraxis (4, 25).  While FGF appears to be responsible for the 
third phase of scleraxis expression, FGF does not appear to be responsible for 
the first and second phases of scleraxis expression (4).  Edom-Vovard and 
Duprez (4) suggested that a member of the GDF family is a likely candidate for 
the regulation of scleraxis expression during the first and second phases of early 
tendon development.  To determine if myostatin induces the expression of 
scleraxis during the first and second phases of early tendon development, a 
double transgenic animal model could be utilized.  Crossing the myostatin 
deficient mice with the ScxGFP line of mice that contain a GFP reporter linked to 
the scleraxis promoter (23) to obtain MSTN-/-ScxGFP mice would create a model 
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organism that would allow for the visualization of scleraxis expression in the 
absence of myostatin at various stages of development.  Comparing GFP 
intensity between MSTN+/+ScxGFP and MSTN-/-ScxGFP mice would be a useful 
first step to determine if myostatin is the cytokine that induces the first two 
phases of scleraxis expression.  The most likely interpretation is that compared 
with MSTN+/+ScxGFP mice, the GFP intensity in the tendon primordia of MSTN-/-
ScxGFP mice is severely depressed. 
Study 2 – Myostatin-mediated biochemical modifications of tendons. 
Compared with MSTN+/+ mice, the tendons of MSTN-/- mice had a two-fold 
greater peak stress, less than half of the peak strain, and a fourteen-fold greater 
peak stiffness.  Furthermore, the fibroblast density of the tendons of the MSTN-/- 
mice was only half that of the MSTN+/+ mice.  While the hypocellularity may 
explain the increase in stiffness, as fibroblasts can break the spontaneous cross-
links that form between collagen molecules, changes in the activities of other 
enzymes might also occur that regulate tendon mechanical properties.  Lysyl 
oxidase is the chief enzyme that can form cross-links between collagen 
molecules (6).  In addition, elastin is a structural protein that allows tendon to 
have a greater peak stress (8).  Determining the expression of lysyl oxidase and 
elastin in tendon might reveal the molecular mechanism behind the myostatin-
mediated regulation of tendon mechanical properties.  Based on the stiffness and 
peak strain data, myostatin might promote the expression of lysyl oxidase and 
elastin in tendon tissue. 
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Study 3 – Regulation of Tendon Fibroblast Proliferation by Tenomodulin.  
Tenomodulin is a type II transmembrane protein that promotes the proliferation of 
tendon fibroblasts (3), but the molecular mechanisms behind the actions of 
tenomodulin are not known.  The tenomodulin protein consists of two domains, 
an N-terminal transmembrane anchor domain and a C-terminal extracellular 
domain (26).  The C-terminal peptide is cleaved and presumably interacts with 
other receptors on the plasma membrane, but the identities of these receptors 
are not known.  To determine if the C-terminal peptide of tenomodulin interacts 
with receptors on the plasma membrane, recombinant c-myc tagged C-terminal 
tenomodulin peptide could be incubated with tendon fibroblast cells followed by 
treatment with a crosslinking reagent.  The cell homogenates would then be 
subjected to immunoprecipitation with an antibody against c-myc.  The pull down 
would then be treated with a reagent to reverse the crosslinking and samples 
would be separated using 2D SDS-PAGE.  Proteins would be removed from the 
gel and subjected to N-terminal sequencing.  The amino acid sequence data 
could then be used to search for possible receptors with which the C-terminal 
peptide of tenomodulin interacts.  The underlying mechanism could be that the 
C-terminal tenomodulin peptide interacts with a receptor that controls cell 
proliferation, but currently there is no basis for the selection of a particular 
receptor.  Identifying the receptors with which tenomodulin interacts is the first 
step in determining the molecular mechanisms behind the tenomodulin-mediated 




 The studies described in this thesis demonstrate that myostatin not only 
has a profound impact on the structure and function of muscle tissue, but also on 
the structure and function of tendon tissue.  While initially characterized as a 
cytokine that regulates skeletal muscle function, myostatin also has important 
roles in tendon, cardiac, bone, mammary and adipose tissue (5, 11, 18, 20, 30).   
 From an evolutionary perspective, an interesting question is:  Why is there 
a gene for myostatin?  The presence of larger, stronger muscles would appear to 
be beneficial for many aspects of everyday life.  All vertebrate species have a 
myostatin gene (22), and fish have two copies (14).  While myostatin has a 
controversial role in metabolism, one potential role of myostatin in metabolism is 
to divert food energy to fat, instead of to muscle (5, 7, 13, 18, 19, 30, 31).  
Diverting food energy to fat instead of muscle would presumptively better enable 
an animal to survive during periods of low food availability.  A recent study 
explored the adaptive evolution of myostatin in the human genome (24).  The 
authors of this study concluded that positive natural selection has acted on the 
myostatin gene, but acknowledged that the amount and rate of polymorphisms at 
the myostatin locus may suggest an evolutionarily recent decline in natural 
selective pressure for myostatin.  While not all polymorphisms lead to a loss of 
function mutation, the greater the rate of polymorphisms, the greater the chance 
of developing a loss of function mutation.  The authors rejected this decline in 
selective pressure at the myostatin locus based entirely on the long history of 
conservation of the myostatin gene across all vertebrate species (24).  The 
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results of this thesis argue against a decline in the natural selective pressure at 
the myostatin gene.  The studies in Chapter II indicate that the MSTN+/- mice 
generate greater forces, without incurring an increased susceptibility to injury.  In 
the Whippet breed of racing dogs, a natural loss of the functional mutation in the 
myostatin gene has arisen (21).  The MSTN+/- and MSTN-/- whippets are known 
as "Bully Whippets" and are considerably faster than their MSTN+/+ counterparts 
(21).  While we did not directly assess the amount of adipose tissue, the MSTN+/- 
mice appear to be leaner than their MSTN+/+ littermates.  We are currently 
conducting a longevity study of MSTN+/+, MSTN+/-, and MSTN-/- mice.  While the 
study is still ongoing, our preliminary results indicate that the MSTN+/- mice have 
an 8 month longer maximum longevity than either the MSTN+/+ or MSTN-/- mice.  
While the long history of selective pressure being applied at the myostatin locus 
may have helped our ancestors survive through periods of famine, in the 
developed world, currently most humans have access to a virtually unlimited 
source of food energy.  The increased rate of polymorphisms does suggest a 
decline in selective pressure at the myostatin locus.  With an unlimited access to 
food energy, the "larger, faster, stronger, leaner, longer-lived" phenotype of 
MSTN+/- organisms has clear advantages over the wild type phenotype.  A 
pharmaceutical inhibitor of myostatin, Stamulumab (Myo-029, Wyeth), is 
currently in clinical trials in the USA and Europe.  Stamulumab is not yet 
available for prescription in the USA, but is available for purchase in China and 
Korea.  Inhibition of myostatin appears to be a practical and potentially useful 
treatment for many muscle wasting conditions and to counteract the decline in 
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muscle mass that occurs with aging.  Future studies that determine the long term 
safety and efficacy of the use of myostatin inhibitors are warranted.  Doping 
control policies and procedures for myostatin inhibitors must also be developed 
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